Patent Grant
12364385
The present inventive concepts relate generally to imaging systems, and in particular, intravascular imaging systems including imaging probes and delivery devices.
Imaging probes have been commercialized for imaging various internal locations of a patient, such as an intravascular probe for imaging a patient's heart. Current imaging probes are limited in their ability to reach certain anatomical locations due to their size and rigidity. Current imaging probes are inserted over a guidewire, which can compromise their placement and limit use of one or more delivery catheters through which the imaging probe is inserted. There is a need for imaging systems that include probes with reduced diameter and high flexibility, as well as systems with one or more delivery devices compatible with these improved imaging probes.
According to one aspect of the present inventive concepts, an imaging system for a patient comprising an imaging probe. The imaging probe comprises: an elongate shaft comprising a proximal end, a distal portion, and a lumen extending between the proximal end and the distal portion; a rotatable optical core comprising a proximal end and a distal end, and at least a portion of the rotatable optical core is positioned within the lumen of the elongate shaft; an optical assembly positioned proximate the distal end of the rotatable optical core, the optical assembly configured to direct light to tissue and collect reflected light from the tissue; a damping fluid positioned between the elongate shaft and the rotatable optical core and configured to reduce non-uniform rotation of the optical assembly; and a fluid pressurization element configured to increase the pressure of the damping fluid to reduce the presence of bubbles proximate the optical assembly; an imaging assembly constructed and arranged to optically couple to the imaging probe, the imaging assembly configured to emit light into the imaging probe and receive the reflected light collected by the optical assembly.
In some embodiments, the fluid pressurization element is configured to reduce bubble formation.
In some embodiments, the fluid pressurization element is configured to reduce the growth of one or more bubbles.
In some embodiments, the fluid pressurization element is configured to reduce the size of one or more bubbles.
In some embodiments, the system comprises an optical beam path, and the fluid pressurization element is configured to propel one or more bubbles to a location remote from the optical beam path.
In some embodiments, the fluid pressurization element is configured to create a pressure gradient within the damping fluid.
In some embodiments, the fluid pressurization element is configured to increase the pressure of the damping fluid for a limited period of time.
In some embodiments, the fluid pressurization element is configured to increase the pressure of the damping fluid intermittently. The fluid pressurization element can be configured to increase the pressure of the damping fluid only when imaging can be occurring. The fluid pressurization element can be configured to increase the pressure of the damping fluid only when the rotatable optical core is rotated. The fluid pressurization element can be configured to increase the pressure of the damping fluid for discrete time periods of no more than two minutes. The fluid pressurization element can be configured to increase the pressure of the damping fluid for discrete time periods of no more than 30 seconds. The fluid pressurization element can be configured to increase the pressure of the damping fluid for discrete time periods of no more than five seconds.
In some embodiments, the fluid pressurization element is configured to generate a pressure of the damping fluid of at least: 3.6 psi; 5.0 psi; 10 psi; 15 psi; 20 psi; 30 psi; and/or 40 psi.
In some embodiments, the fluid pressurization element is configured to generate a pressure of the damping fluid of at least: 75 psi; 100 psi; 125 psi; and/or 150 psi.
In some embodiments, the fluid pressurization element is configured to generate a high pressure area and a low pressure area within the damping fluid.
In some embodiments, the fluid pressurization element comprises a pressurization source. The pressurization source can comprise a pump. The fluid pressurization element can further comprise a valve configured to allow passage of gas while limiting passage of the damping fluid.
In some embodiments, the fluid pressurization element is configured to increase the pressure of the damping fluid when the rotatable optical core is rotated. The fluid pressurization element can comprise at least one projection that radially extends from the rotatable optical core. The at least one projection can comprise multiple projections that each radially extend from the rotatable optical core. The fluid pressurization element can comprise a helical projection that radially extends from the rotatable optical core. The fluid pressurization element can comprise a helical coil surrounding the rotatable optical core. The helical coil can have uniform pitch. The fluid pressurization element can comprise an element with a propeller-like construction. The fluid pressurization element can comprise a spring-type element.
In some embodiments, the fluid pressurization element comprises a first fluid pressurization element and a second fluid pressurization element, and the second fluid pressurization element is positioned proximal to the first fluid pressurization element. The second fluid pressurization element can be configured to prime the first fluid pressurization element when rotated.
In some embodiments, the fluid pressurization element is adhesively attached to the rotatable optical core.
In some embodiments, the fluid pressurization element is molded on and/or with the rotatable optical core.
In some embodiments, the fluid pressurization element is fused onto the rotatable optical core.
In some embodiments, the fluid pressurization element is formed into the rotatable optical core. The system can be formed onto the rotatable optical core via deposition and/or three-dimensional (3D) printing.
In some embodiments, the fluid pressurization element comprises a material selected from the group consisting of: metal; plastic; stainless steel; nickel-titanium alloy; nylon; polyether ether ketone; polyimide; and combinations thereof.
In some embodiments, the rotatable optical core comprises a diameter D1, and the elongate shaft lumen comprises a diameter D2, and the fluid pressurization element extends from the rotatable optical core with a radial height H1, and H1 comprises at least 5% and/or no more than 95% of half the difference between D1 and D2.
In some embodiments, the rotatable optical core comprises a diameter D1, and the elongate shaft lumen comprises a diameter D2, and the fluid pressurization element extends from the rotatable optical core with a radial height H1, and a clearance C1 comprises one half the difference between D1 and D2 minus H1, and clearance C1 comprises a length of no more than 100 μm and/or no more than 75 μm.
In some embodiments, the fluid pressurization element comprises a covering. The covering can comprise an element selected from the group consisting of: sheath; heat shrink tube; painted on coating; sprayed on coating; and combinations thereof.
In some embodiments, the fluid pressurization element is further configured to produce a motive force, and the motive force is configured to translate the rotatable optical core. The fluid pressurization element can be configured to advance the rotatable optical core when rotated in a first direction and to retract the rotatable optical core when rotated in a second direction which is opposite the first direction.
In some embodiments, the damping fluid comprises a non-Newtonian fluid.
In some embodiments, the damping fluid comprises a shear-thinning fluid.
In some embodiments, the damping fluid comprises a static viscosity of at least 500 centipoise. The damping fluid can comprise a shear viscosity that is less than its static viscosity. The damping fluid can comprise a static viscosity to shear viscosity ratio of at least 1.2:1 and/or no more than 100:1.
In some embodiments, the damping fluid comprises a first fluid and a second fluid. The first fluid can comprise a low viscosity fluid and the second fluid can comprise a high viscosity fluid.
In some embodiments, the damping fluid comprises a low viscosity fluid configured to reduce bubble formation. The damping fluid can comprise a fluid with a viscosity of no more than 1000 centipoise.
In some embodiments, the damping fluid comprises a fluid with high surface tension configured to reduce bubble formation. The damping fluid can comprise a fluid with a surface tension of at least 40 dynes/cm.
In some embodiments, the imaging probe comprises a distal portion with a diameter of no more than 0.020″. The imaging probe distal portion can comprise a diameter of no more than 0.016″.
In some embodiments, the imaging probe further includes a sealing element in a distal portion of the elongate shaft.
According to another aspect of the present inventive concepts, an imaging probe comprises: an elongate shaft comprising a proximal end, a distal portion, and a lumen extending between the proximal end and the distal portion; a rotatable optical core comprising a proximal end and a distal end, and at least a portion of the rotatable optical core is positioned within the lumen of the elongate shaft; and an optical assembly positioned proximate the distal end of the rotatable optical core, the optical assembly configured to direct light to tissue and collect reflected light from the tissue; and the shaft comprises a proximal shaft and a distal shaft attached thereto; and the proximal shaft comprises a first tubular member with a first lumen, and the distal shaft comprises a second tubular member with a second lumen, and the shaft further comprises a third tubular member that extends into the first lumen and the second lumen, and the shaft further comprises a fourth tubular member with a proximal portion that surrounds a distal portion of the first tubular member and a distal portion positioned between a proximal portion of the second tubular member and the third tubular member.
In some embodiments, the first tubular member comprises a spiral cut hypotube.
In some embodiments, the second tubular member comprises a transparent material.
In some embodiments, the third tubular member comprises an outer diameter that is greater than the first lumen.
In some embodiments, the fourth tubular member comprises a heat shrink material.
In some embodiments, the imaging probe further comprises adhesive positioned between two or more of the first tubular member, second tubular member, third tubular member, and/or fourth tubular member.
In some embodiments, the imaging probe further comprises a fluid propulsion element with a diameter D1, and the third tubular member comprises a lumen with a diameter less than D1.
In some embodiments, the second tubular member comprises a projection extending toward the third tubular member.
In some embodiments, the second tubular member comprises a maximum diameter proximate the third tubular member, and the fourth tubular member comprises a maximum diameter proximate the third tubular member, and each maximum diameter does not exceed a diameter of 0.02″, 0.0175″, and/or 0.0155″.
In some embodiments, the fluid pressurization element comprises a first fluid pressurization element and a second fluid pressurization element. The first and second pressurization elements can create opposing pressure gradients when rotated.
According to another aspect of the invention, a method of producing a fluid propulsion element for an optical probe comprises: providing a tube with a mandrel inserted therethrough; creating two or more helical channels along the length of the tube; removing a first fluid propulsion element from the mandrel; and removing a second fluid propulsion element from the mandrel.
In some embodiments, the method further comprises producing a first optical probe using at least the first fluid propulsion element. The method can further comprise producing a second optical probe using the second fluid propulsion element.
The technology described herein, along with the attributes and attendant advantages thereof, will best be appreciated and understood in view of the following detailed description taken in conjunction with the accompanying drawings in which representative embodiments are described by way of example.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. The content of all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety for all purposes.
Reference will now be made in detail to the present embodiments of the technology, examples of which are illustrated in the accompanying drawings. Similar reference numbers may be used to refer to similar components. However, the description is not intended to limit the present disclosure to particular embodiments, and it should be construed as including various modifications, equivalents, and/or alternatives of the embodiments described herein.
It will be understood that the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) when used herein, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It will be further understood that, although the terms first, second, third, etc. may be used herein to describe various limitations, elements, components, regions, layers and/or sections, these limitations, elements, components, regions, layers and/or sections should not be limited by these terms. These terms are only used to distinguish one limitation, element, component, region, layer or section from another limitation, element, component, region, layer or section. Thus, a first limitation, element, component, region, layer or section discussed below could be termed a second limitation, element, component, region, layer or section without departing from the teachings of the present application.
It will be further understood that when an element is referred to as being “on”, “attached”, “connected” or “coupled” to another element, it can be directly on or above, or connected or coupled to, the other element, or one or more intervening elements can be present. In contrast, when an element is referred to as being “directly on”, “directly attached”, “directly connected” or “directly coupled” to another element, there are no intervening elements present. Other words used to describe the relationship between elements should be interpreted in a like fashion (e.g. “between” versus “directly between,” “adjacent” versus “directly adjacent,” etc.).
It will be further understood that when a first element is referred to as being “in”, “on” and/or “within” a second element, the first element can be positioned: within an internal space of the second element, within a portion of the second element (e.g. within a wall of the second element); positioned on an external and/or internal surface of the second element; and combinations of one or more of these.
As used herein, the term “proximate”, when used to describe proximity of a first component or location to a second component or location, is to be taken to include one or more locations near to the second component or location, as well as locations in, on and/or within the second component or location. For example, a component positioned proximate an anatomical site (e.g. a target tissue location), shall include components positioned near to the anatomical site, as well as components positioned in, on and/or within the anatomical site.
Spatially relative terms, such as “beneath,” “below,” “lower,” “above,” “upper” and the like may be used to describe an element and/or feature's relationship to another element(s) and/or feature(s) as, for example, illustrated in the figures. It will be further understood that the spatially relative terms are intended to encompass different orientations of the device in use and/or operation in addition to the orientation depicted in the figures. For example, if the device in a figure is turned over, elements described as “below” and/or “beneath” other elements or features would then be oriented “above” the other elements or features. The device can be otherwise oriented (e.g. rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
The terms “reduce”, “reducing”, “reduction” and the like, where used herein, are to include a reduction in a quantity, including a reduction to zero. Reducing the likelihood of an occurrence shall include prevention of the occurrence. Correspondingly, the terms “prevent”, “preventing”, and “prevention” shall include the acts of “reduce”, “reducing”, and “reduction”, respectively.
The term “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, “A and/or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
The term “one or more”, where used herein can mean one, two, three, four, five, six, seven, eight, nine, ten, or more, up to any number.
The terms “and combinations thereof” and “and combinations of these” can each be used herein after a list of items that are to be included singly or collectively. For example, a component, process, and/or other item selected from the group consisting of: A; B; C; and combinations thereof, shall include a set of one or more components that comprise: one, two, three or more of item A; one, two, three or more of item B; and/or one, two, three, or more of item C.
In this specification, unless explicitly stated otherwise, “and” can mean “or”, and “or” can mean “and”. For example, if a feature is described as having A, B, or C, the feature can have A, B, and C, or any combination of A, B, and C. Similarly, if a feature is described as having A, B, and C, the feature can have only one or two of A, B, or C.
The expression “configured (or set) to” used in the present disclosure may be used interchangeably with, for example, the expressions “suitable for”, “having the capacity to”, “designed to”, “adapted to”, “made to” and “capable of” according to a situation. The expression “configured (or set) to” does not mean only “specifically designed to” in hardware. Alternatively, in some situations, the expression “a device configured to” may mean that the device “can” operate together with another device or component.
As used herein, the term “threshold” refers to a maximum level, a minimum level, and/or range of values correlating to a desired or undesired state. In some embodiments, a system parameter is maintained above a minimum threshold, below a maximum threshold, within a threshold range of values, and/or outside a threshold range of values, such as to cause a desired effect (e.g. efficacious therapy) and/or to prevent or otherwise reduce (hereinafter “prevent”) an undesired event (e.g. a device and/or clinical adverse event). In some embodiments, a system parameter is maintained above a first threshold (e.g. above a first temperature threshold to cause a desired therapeutic effect to tissue) and below a second threshold (e.g. below a second temperature threshold to prevent undesired tissue damage). In some embodiments, a threshold value is determined to include a safety margin, such as to account for patient variability, system variability, tolerances, and the like. As used herein, “exceeding a threshold” relates to a parameter going above a maximum threshold, below a minimum threshold, within a range of threshold values and/or outside of a range of threshold values.
As described herein, “room pressure” shall mean pressure of the environment surrounding the systems and devices of the present inventive concepts. Positive pressure includes pressure above room pressure or simply a pressure that is greater than another pressure, such as a positive differential pressure across a fluid pathway component such as a valve. Negative pressure includes pressure below room pressure or a pressure that is less than another pressure, such as a negative differential pressure across a fluid component pathway such as a valve. Negative pressure can include a vacuum but does not imply a pressure below a vacuum. As used herein, the term “vacuum” can be used to refer to a full or partial vacuum, or any negative pressure as described hereabove.
The term “diameter” where used herein to describe a non-circular geometry is to be taken as the diameter of a hypothetical circle approximating the geometry being described. For example, when describing a cross section, such as the cross section of a component, the term “diameter” shall be taken to represent the diameter of a hypothetical circle with the same cross sectional area as the cross section of the component being described.
The terms “major axis” and “minor axis” of a component where used herein are the length and diameter, respectively, of the smallest volume hypothetical cylinder which can completely surround the component.
As used herein, the term “functional element” is to be taken to include one or more elements constructed and arranged to perform a function. A functional element can comprise a sensor and/or a transducer. In some embodiments, a functional element is configured to deliver energy and/or otherwise treat tissue (e.g. a functional element configured as a treatment element). Alternatively or additionally, a functional element (e.g. a functional element comprising a sensor) can be configured to record one or more parameters, such as a patient physiologic parameter; a patient anatomical parameter (e.g. a tissue geometry parameter); a patient environment parameter; and/or a system parameter. In some embodiments, a sensor or other functional element is configured to perform a diagnostic function (e.g. to gather data used to perform a diagnosis). In some embodiments, a functional element is configured to perform a therapeutic function (e.g. to deliver therapeutic energy and/or a therapeutic agent). In some embodiments, a functional element comprises one or more elements constructed and arranged to perform a function selected from the group consisting of: deliver energy; extract energy (e.g. to cool a component); deliver a drug or other agent; manipulate a system component or patient tissue; record or otherwise sense a parameter such as a patient physiologic parameter or a system parameter; and combinations of one or more of these. A functional element can comprise a fluid and/or a fluid delivery system. A functional element can comprise a reservoir, such as an expandable balloon or other fluid-maintaining reservoir. A “functional assembly” can comprise an assembly constructed and arranged to perform a function, such as a diagnostic and/or therapeutic function. A functional assembly can comprise an expandable assembly. A functional assembly can comprise one or more functional elements.
The term “transducer” where used herein is to be taken to include any component or combination of components that receives energy or any input, and produces an output. For example, a transducer can include an electrode that receives electrical energy, and distributes the electrical energy to tissue (e.g. based on the size of the electrode). In some configurations, a transducer converts an electrical signal into any output, such as light (e.g. a transducer comprising a light emitting diode or light bulb), sound (e.g. a transducer comprising a piezo crystal configured to deliver ultrasound energy), pressure, heat energy, cryogenic energy, chemical energy; mechanical energy (e.g. a transducer comprising a motor or a solenoid), magnetic energy, and/or a different electrical signal (e.g. a Bluetooth or other wireless communication element). Alternatively or additionally, a transducer can convert a physical quantity (e.g. variations in a physical quantity) into an electrical signal. A transducer can include any component that delivers energy and/or an agent to tissue, such as a transducer configured to deliver one or more of: electrical energy to tissue (e.g. a transducer comprising one or more electrodes); light energy to tissue (e.g. a transducer comprising a laser, light emitting diode and/or optical component such as a lens or prism); mechanical energy to tissue (e.g. a transducer comprising a tissue manipulating element); sound energy to tissue (e.g. a transducer comprising a piezo crystal); chemical energy; electromagnetic energy; magnetic energy; and combinations of one or more of these.
As used herein, the term “fluid” can refer to a liquid, gas, gel, or any flowable material, such as a material which can be propelled through a lumen and/or opening.
It is appreciated that certain features of the inventive concepts, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the inventive concepts which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. For example, it will be appreciated that all features set out in any of the claims (whether independent or dependent) can be combined in any given way.
It is to be understood that at least some of the figures and descriptions of the inventive concepts have been simplified to focus on elements that are relevant for a clear understanding of the inventive concepts, while eliminating, for purposes of clarity, other elements that those of ordinary skill in the art will appreciate may also comprise a portion of the inventive concepts. However, because such elements are well known in the art, and because they do not necessarily facilitate a better understanding of the invention, a description of such elements is not provided herein.
Terms defined in the present disclosure are only used for describing specific embodiments of the present disclosure and are not intended to limit the scope of the present disclosure. Terms provided in singular forms are intended to include plural forms as well, unless the context clearly indicates otherwise. All of the terms used herein, including technical or scientific terms, have the same meanings as those generally understood by an ordinary person skilled in the related art, unless otherwise defined herein. Terms defined in a generally used dictionary should be interpreted as having meanings that are the same as or similar to the contextual meanings of the relevant technology and should not be interpreted as having ideal or exaggerated meanings, unless expressly so defined herein. In some cases, terms defined in the present disclosure should not be interpreted to exclude the embodiments of the present disclosure.
Provided herein are imaging systems for a patient including an imaging probe and an imaging assembly that optically couples to the imaging probe. The probe comprises an elongate shaft, a rotatable optical core, and an optical assembly. The rotatable optical core is positioned within a lumen of the elongate shaft. The optical assembly is positioned proximate a distal end of the optical core and is configured to direct light to tissue and collect reflected light from tissue. The imaging assembly, when optically coupled to the imaging probe, is configured to emit light into the imaging probe and receive the reflected light collected by the optical assembly, such as to provide images of blood vessels and devices positioned within blood vessels. The probe can include a damping fluid positioned between the elongate shaft and the rotatable optical core, and this damping fluid can be configured to reduce non-uniform rotation of the optical assembly, thus reducing undesired distortions of images produced by the system. The probe can further include a fluid pressurization element configured to increase the pressure of the damping fluid to reduce presence of bubbles proximate the optical assembly (e.g. bubbles that would limit or reduce the quality of images produced by the system).
Imaging of blood vessels is the primary diagnostic tool when planning and applying therapies such as thrombolytic drugs or stent retrievers for clot removal (e.g. ischemic stroke) or coils, flow diverters and other devices for aneurysm repair (e.g. hemorrhagic stroke). External, non-invasive, imaging such as x-ray angiography or magnetic resonance imaging (MRI) are the primary imaging techniques but such techniques provide information only on the vessel size and shape, and with moderate resolution (˜0.2 mm or 200 um). Such levels of resolution do not permit the imaging of important smaller features present in the vasculature. An inability to adequately image these vessels limits pre-procedural planning and acute assessment of therapeutic results. These imaging technologies are further limited in effectiveness due to the shadowing and local image obliteration created by the therapies themselves in the case of coils. Thus, there is a desire to also perform the intravascular imaging of the present inventive concepts to examine the detailed morphology of the interior vessel wall and/or to better plan and assess the results of catheter-based interventions. Currently, intravascular imaging techniques such as Intravascular Ultrasound (IVUS) and intravascular Optical Coherence Tomography (OCT) have been developed and approved for use in the coronary arteries. IVUS is also used in the larger peripheral vasculature. However, intravascular imaging has not been extended into the neurological vessels except for the larger carotid arteries. This limitation is due mainly to two reasons: the neurological vessel sizes can become very small, on the order of 1 mm in diameter or less, and the vessel tortuosity becomes quite high. Therefore, there is a need for smaller and more flexible imaging probes, such as probes that can safely and effectively navigate the tortuous carotid sinus to reach and image the mid-cranial artery, as well as its more distal branches and segments.
Due to the fundamental limits of ultrasound resolution, especially the unavoidable beam spreading when small transducers are used, optical techniques are preferred. In particular, with the advent of new light sources such as broad band superluminescent light emitting diodes (SLEDs), super-continuum lasers, compact swept-frequency light sources, micro-optical systems, and interferometric detection of the return light using techniques such as Optical Coherence Tomography (OCT), all of which are compatible with single-mode fibers, the use of optical techniques becomes highly advantageous both from a clinical performance as well as commercial viewpoint. Furthermore, the use of single mode fibers allows the smallest possible imaging probes to be considered.
In general, to create a three-dimensional (3D) view of the interior wall of a blood vessel, light delivered by distally located imaging optics of an inserted probe can be swept over the surface of the lumen by simultaneous axial translation (‘pull-back’) and rotation of the optics and an attached fiber. To facilitate accurate, distortion-free images, the distal rotation rate should be uniform in speed. Due to size and cost, drive motors that cause the rotation are located proximally, outside the patient and separate from the imaging probe (e.g. configured in a reusable arrangement for use with multiple imaging probes). The natural tendency of the probe's fiber is to “whip” at the distal end, creating an effect known as Non-Uniform Rotational Distortion (NURD). To overcome this undesired effect, tightly wound, spring-like coils known as torque wires, with the fiber located in the center of the coil, have been used to reduce non-uniform rotation to the distal optics. These torque wires can add bulk to the catheter (e.g. increase in diameter), have tortuosity limits beyond which NURD reappears, and can be costly. Furthermore, torque wires are sensitive to the total accumulated tortuosity integrated along the length of the catheter, and since torque wires must be attached to a proximal drive source, this total integrated tortuosity can become significant (e.g. and cause NURD to reappear). Since uniform rotation is only required for the optics at the distal tip, the rotation of components proximal to the distal optics need not be as well controlled; in other words, the fiber can twist and untwist in the proximal regions as the tortuosity varies without generating NURD, as long as the rotational speed of the distal optics remains relatively constant. Thus, a configuration in which uniform rotation is controlled for the distal optics without a torque wire can both avoid numerous limitations as well as provide numerous advantages.
To overcome the limitations of torque wires, damping fluids have been used to control rotational speed variations. For example, U.S. Pat. No. 6,891,984 (the '984 patent), describes the use of viscous fluids to cause fiber “wind-up” and rotational energy storage. The unwinding rate is also determined by the fluid's viscosity, which can provide an effective feedback mechanism for rotational control. Any fluid over the lens needs to meet desired optical properties, in particular an optical index within an acceptable range to minimize cylindrical distortion, as well as a low absorption at the operating wavelengths. The fluid selected can comprise a biocompatible fluid, since is it temporarily positioned inside the body. If not biocompatible, additional protective layers can be added to guard against undesirable single-fault conditions (e.g. leak conditions).
Systems of the present inventive concepts can include a non-Newtonian fluid and/or shear-thinning fluid such as to accommodate high-speed rotation, such as is described in applicant's co-pending U.S. patent application Ser. No. 15/566,041, titled “Micro-Optic Probes for Neurology”, filed Oct. 12, 2017.
Fluid-based rotational control solutions (e.g. fluid damping solutions) all suffer from a susceptibility to bubbles forming within the fluid. Although the bubbles will have, in general, a small effect on the mechanical performance, it is easily appreciated that a bubble located in the path of delivered and/or received light (the “optical beam path”) will have significant undesired effects on the image quality. Bubble formation is inherent with rotating elements in a fluid field, such as via a phenomenon known as cavitation. Fluid-solid interfaces can also create bubbles in the fluid through nucleation, but cavitation is usually dominant with high-speed rotating. Due to the requirement for directing the light beam relatively orthogonal to the probe axis, some asymmetry will exist in the distal optics (e.g. a lens assembly with a beveled distal end configured to direct light 90° from the axis of the distal end of the attached fiber) and thus a propensity for generating low pressure regions at high speed rotation will typically occur.
Cavitation is the presence of small vapor-filled zones (“bubbles”), that are the consequence when a liquid is subjected to rapid changes of pressure that cause the formation of cavities in the regions where the pressure is relatively low. There are several general properties of the system of the present inventive concepts that can be optimized to minimize cavitation and its associated bubble formation. For example, the geometry of the imaging probe (e.g. the spaces in which a damping fluid is positioned) can be constructed and arranged to minimize bubble formation. The viscosity of an included damping fluid can be chosen to limit bubble formation. A damping fluid can comprise a fluid with low vapor pressure and/or low levels of dissolved gas (or gasses). A damping fluid can comprise a fluid that has high surface tension (e.g. to tend to cause bubbles to collapse). A damping fluid can comprise a fluid with low surface tension (e.g. if bubble formation is caused via nucleation), such as a wetting agent. Low viscosity fluids will tend to reduce bubble formation, but they may not effectively control NURD by themselves. Combinations of two or more fluids (e.g. in a stacked arrangement) can be used, such as when one or more sealing elements are included to keep the fluids separated. The low-viscosity fluid can be positioned over the distal optics (e.g. only over the distal optics), and the high viscosity fluid placed proximal to the low viscosity fluid and extending over a relatively longer segment of the imaging probe. In some embodiments, one or more damping fluids are used, wherein the one or more damping fluids comprise: a viscosity chosen to reduce bubble formation; a low vapor pressure; a low level of dissolved gas; a low surface tension; and/or a high surface tension.
In some embodiments, pressure of an included damping fluid (or other fluid) can be increased, such as to cause an effect selected from the group consisting of: reduction of bubble formation; reduced growth of one or more bubbles (e.g. one or more existing bubbles); reduction in size of one or more bubbles (e.g. one or more existing bubbles); propulsion of one or more bubbles to a location remote from the optical beam path; and combinations of these. Increased pressurization of the damping fluid can be performed for a limited time, as prolonged pressurization can cause the fluid to adsorb additional gasses, causing a new vapor pressure to be established. The pressurization elements of the present inventive concepts can be of small size (e.g. compact), so as to be enclosed within the probe. These pressurization elements can be activated (e.g. to generate increased pressure of a damping fluid) only when actual imaging is occurring (e.g. when the fiber and distal optics are rotated at high speeds), such as to avoid establishing an undesired equilibrium condition caused by prolonged pressurization.
All of the above bubble-reducing configurations can be applied individually and/or in combination to prevent, limit, and/or reduce bubble formation proximate the distal optics of the probe.
The systems of the present inventive concepts can include a probe with a fluid pressurization element configured to “minimize a bubble effect” (e.g. reduce the presence of bubbles at one or more locations), which shall include: preventing, limiting, and/or reducing formation of one or more bubbles; limiting and/or reducing the expansion of one or more bubbles; reducing the size of one or more bubbles; and/or moving one or more bubbles away from the optical beam path (e.g. moving one or more bubbles away from the optical assembly transmitting light to and/or from tissue).
Referring now to
In some embodiments, imaging probe 100 and/or another component of imaging system 10 can be of similar construction and arrangement to the similar components described in applicant's co-pending U.S. patent application Ser. No. 15/566,041, titled “Micro-Optic Probes for Neurology”, filed Oct. 12, 2017, and/or applicant's co-pending U.S. Provisional Patent Application Ser. No. 62/732,114, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2018. Imaging probe 100 can be constructed and arranged to collect image data from a patient site, such as an intravascular cardiac site, an intracranial site, or other site accessible via the vasculature of the patient. In some embodiments, imaging system 10 can be of similar construction and arrangement to the similar systems and their methods of use described in applicant's co-pending U.S. patent application Ser. No. 15/751,570, titled “Imaging System includes Imaging Probe and Delivery Devices”, filed Feb. 9, 2018.
Delivery catheter 80 comprises an elongate shaft, shaft 81, with a lumen 84 therethrough, and a connector 82 positioned on its proximal end. Connector 82 can comprise a Touhy or other valved connector, such as a valved connector configured to prevent fluid egress from the associated delivery catheter 80 (with and/or without a separate shaft positioned within the connector 82). Connector 82 can comprise a port 83, such as a port constructed and arranged to allow introduction of fluid into delivery catheter 80 and/or for removing fluids from delivery catheter 80. In some embodiments, a flushing fluid, as described herebelow, is introduced via one or more ports 83, such as to remove blood or other undesired material from locations proximate an optical assembly (e.g. from a location proximal to an optical assembly to a location distal to the optical assembly, such as optical assembly 115 described herebelow). Port 83 can be positioned on a side of connector 82 and can include a luer fitting and a cap and/or valve. Shafts 81, connectors 82, and ports 83 can each comprise standard materials and be of similar construction to commercially available introducers, guide catheters, diagnostic catheters, intermediate catheters and microcatheters used in interventional procedures. Delivery catheter 80 can comprise a catheter configured to deliver imaging probe 100 (via lumen 84) to an intracerebral location, an intracardiac location, and/or another location within a patient.
Imaging system 10 can comprise two or more delivery catheters 80, such as three or more delivery catheters 80. Multiple delivery catheters 80 can comprise at least a vascular introducer, and other delivery catheters 80 that can be inserted into the patient therethrough, after the vascular introducer is positioned through the skin of the patient. Two or more delivery catheters 80 can collectively comprise sets of inner diameters (IDs) and outer diameters (ODs) such that a first delivery catheter 80 slidingly receives a second delivery catheter 80 (e.g. the second delivery catheter OD is less than or equal to the first delivery catheter ID), and the second delivery catheter 80 slidingly receives a third delivery catheter 80 (e.g. the third delivery catheter OD is less than or equal to the second delivery catheter ID), and so on. In these configurations, the first delivery catheter 80 can be advanced to a first anatomical location, the second delivery catheter 80 can be advanced through the first delivery catheter to a second anatomical location distal or otherwise remote (hereinafter “distal”) to the first anatomical location, and so on as appropriate, using sequentially smaller diameter delivery catheters 80. Probe 100 can be advanced through and/or alongside one or more of the delivery catheters 80 (e.g. through the lumen of the smallest delivery catheter 80). In some embodiments, delivery catheters 80 can be of similar construction and arrangement to the similar components described in applicant's co-pending U.S. patent application Ser. No. 15/751,570, titled “Imaging System includes Imaging Probe and Delivery Devices”, filed Feb. 9, 2018.
Imaging probe 100 comprises an elongate body, comprising one or more elongate shafts and/or other tubes, elongate shaft 120 herein. Shaft 120 comprises a proximal end 1201, distal end 1209, and a lumen 1205 extending therebetween. In some embodiments, lumen 1205 includes multiple coaxial lumens within the one or more elongate shafts 120, such as one or more lumens abutting each other to define a single lumen 1205. In some embodiments, at least a portion of shaft 120 comprises a torque shaft. In some embodiments, a portion of shaft 120 comprises a braided construction. Shaft 120 operably surrounds a rotatable optical fiber, optical core 110 (e.g. optical core 110 is positioned within lumen 1205), comprising a proximal end 1101 and a distal end 1109 (proximal end 1101 not shown, but proximate proximal end 1201 of shaft 120). Optical core 110 can comprise a dispersion shifted optical fiber, such as a depressed cladding dispersion shifted fiber. Shaft 120 further comprises a distal portion 1208, including a transparent window, window 130 (e.g. a window that is relatively transparent to the one or more frequencies of light transmitted through optical core 110). Window 130 can comprise a full circumferential portion of distal portion 1208 of shaft 120. An optical assembly, optical assembly 115, is operably attached to the distal end 1109 of optical core 110 (e.g. such that optical assembly 115 rotates in unison with optical core 110). Optical assembly 115 is positioned within window 130 of shaft 120. A connector assembly, connector assembly 150, is positioned on the proximal end of shaft 120. Connector assembly 150 operably attaches imaging probe 100 to rotation assembly 500, such that rotation assembly 500 is operably attached to optical core 110. Rotation assembly 500 can be configured to rotate optical core 110 within shaft 120, as described herein. Connector assembly 150 can be of similar construction and arrangement to similar components described in applicant's co-pending International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018, and applicant's co-pending U.S. Provisional Patent Application Ser. No. 62/732,114, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2018. A second connector, pullback connector 858, is positioned on shaft 120. Connector 858 can be removably attached and/or adjustably positioned along the length of shaft 120. Connector 858 can be positioned along shaft 120, such as by an operator, proximate the proximal end of delivery catheter 80 after imaging probe 100 has been inserted into a patient via delivery catheter 80 (e.g. proximal to connector 82 of delivery catheter 80). Shaft 120 can comprise a portion between connector assembly 150 and the placement location of connector 858 that accommodates slack in shaft 120, a proximal portion of shaft 120 (e.g. a proximal portion of imaging probe 100), service loop 185.
Imaging probe 100 can comprise one or more visualizable markers along its length (e.g. along shaft 120), markers 131a-b shown (marker 131 herein). Marker 131 can comprise markers selected from the group consisting of: radiopaque markers; ultrasonically reflective markers; magnetic markers; ferrous material; visible markers; and combinations of one or more of these. In some embodiments, marker 131 comprises a marker positioned at a location (e.g. a location within and/or at least proximate distal portion 1208) to assist an operator of imaging system 10 in performing a pullback procedure (e.g. a pullback procedure in which fluoroscopy and/or external ultrasound imaging is used), such as to cause distal end 1209 of shaft 120 to be positioned at a location distal to the proximal end of an implant after the pullback is completed (e.g. so that imaging probe 100 can be safely advanced through the implant after the pullback).
In some embodiments, imaging probe 100 includes a viscous damping fluid or other damping material, gel 180, positioned within lumen 1205 of shaft 120, and configured to reduce non-uniform rotation of optical assembly 115. Gel 180 can surround at least a distal portion of optical core 110. Gel 180 can further surround optical assembly 115. Gel 180 can comprise a non-Newtonian fluid, for example a shear-thinning fluid. In some embodiments, gel 180 comprises a static viscosity of at least 500 centipoise, and a shear viscosity that is less than the static viscosity. In these embodiments, the ratio of static viscosity to shear viscosity of gel 180 can be between 1.2:1 and 100:1. Gel 180 can comprise a gel as described in reference to applicant's co-pending U.S. patent application Ser. No. 15/566,041, titled “Micro-Optic Probes for Neurology”, filed Oct. 12, 2017, and applicant's co-pending International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018.
Imaging probe 100 can include a distal tip portion, distal tip 119. In some embodiments, distal tip 119 comprises a spring tip, such as a spring tip configured to improve the “navigability” of imaging probe 100 (e.g. to improve “trackability” and/or “steerability” of imaging probe 100), for example within a tortuous pathway (e.g. within a blood vessel of the brain or heart with a tortuous pathway). In some embodiments, tip 119 comprises a length of between 5 mm and 100 mm (e.g. a spring with a length between 5 mm and 100 mm). Alternatively or additionally, tip 119 can comprise a cap, plug, or other element configured to seal the distal opening of window 130. In some embodiments, tip 119 comprises a radiopaque marker configured to increase the visibility of imaging probe 100 under an X-ray or fluoroscope. In some embodiments, tip 119 comprises a relatively short luminal guidewire pathway to allow “rapid exchange” translation of imaging probe 100.
In some embodiments, at least the distal portion of imaging probe 100 (e.g. the distal portion of shaft 120 surrounding optical assembly 115) comprises an outer diameter of no more than 0.020″, or no more than 0.016″.
In some embodiments, imaging probe 100 is constructed and arranged for use in an intravascular neural procedure (e.g. a procedure in which the blood, vasculature, and other tissue proximate the brain are visualized, and/or devices positioned temporarily or permanently proximate the brain are visualized). An imaging probe 100 configured for use in a neural procedure can comprise an overall length of at least 150 cm, such as a length of approximately 300 cm.
Alternatively or additionally, imaging probe 100 can be constructed and arranged for use in an intravascular cardiac procedure (e.g. a procedure in which the blood, vasculature, and other tissue proximate the heart are visualized, and/or devices positioned temporarily or permanently proximate the heart are visualized). An imaging probe 100 configured for use in a cardiovascular procedure can comprise an overall length of at least 120 cm, such as an overall length of approximately 280 cm. In some embodiments, imaging probe 100 comprises a length of at least 260 cm and/or at most 320 cm.
Rotation assembly 500 operably attaches to connector 150 of imaging probe 100. Rotation assembly 500 can comprise one or more rotary joints, optical connectors, rotational energy sources, and/or linkages, configured to operably attach and rotate optical core 110. Connector 150 can be constructed and arranged to removably attach to rotation assembly 500, and to allow a rotating connection between proximal end 1101 and a rotating fiber optic joint (such as a fiber optic rotary joint or FORJ). Rotation assembly 500 can be of similar construction and arrangement to similar components described in applicant's co-pending International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018, and applicant's co-pending U.S. Provisional Patent Application Ser. No. 62/732,114, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2018. Rotation assembly 500 can be configured to rotate optical core 110 at speeds of at least 100 rotations per second, such as at least 200 rotations per second or 250 rotations per second, or between 20 rotations per second and 1000 rotations per second. Rotation assembly 500 can comprise a rotational energy source selected from the group consisting of: a motor; a servo; a stepper motor (e.g. a stepper motor including a gear box); a linear actuator; a hollow core motor; and combinations thereof. In some embodiments, rotation assembly 500 is configured to rotate optical assembly 115 and optical core 110 in unison.
Retraction assembly 800 operably attaches to imaging probe 100, such as to retract imaging probe 100 relative to a patient access site. A retraction element 850 can operably attach to retraction assembly 800 and imaging probe 100, such as to transfer a retraction force from retraction assembly 800 to imaging probe 100. Retraction element 850 can comprise a conduit 855, surrounding a linkage 856, slidingly received therein. Retraction element 850 can comprise a connector 852, that operably attaches to retraction assembly 800, such that retraction assembly 800 can retract linkage 856 relative to conduit 855. In some embodiments, conduit 855 comprises a connector 857 that operably attaches to a reference point near the patient access site, for example to connector 82 of delivery catheter 80, such as to establish a reference for retraction of imaging probe 100 relative to the patient. Connector 857 can attach to a reference point such as a patient introduction device, surgical table, and/or another fixed or semi fixed point of reference. Linkage 856 releasably attaches to connector 858 of imaging probe 100. Retraction assembly 800 retracts at least a portion of imaging probe 100 (e.g. the portion of imaging probe 100 distal to the attached connector 858), relative to the established reference by retracting linkage 856 relative to conduit 855 (e.g. retract a portion of linkage 856 exiting a portion of conduit 855, as shown). In some embodiments, retraction assembly 800 is configured to retract at least a portion of imaging probe 100 (e.g. at least optical assembly 115 and a portion of shaft 120) at a rate of between 5 mm/sec and 200 mm/sec, or between 5 mm/sec and 100 mm/sec, such as a rate of approximately 60 mm/sec. Additionally or alternatively, the pullback procedure can be performed during a time period of between 0.5 sec and 25 sec, for example approximately 20 sec (e.g. over a distance of 100 mm at 5 mm/sec). Service loop 185 of imaging probe 100 can be positioned between connector 857, and rotation assembly 500, such that imaging probe 100 can be retracted relative to the patient while rotation assembly 500 remains stationary (e.g. attached to the surgical table and/or to a portion of console 50).
Retraction assembly 800 further comprises a motive element configured to retract linkage 856. In some embodiments, the motive element comprises a linear actuator, a worm drive operably attached to a motor, a pulley system, and/or other linear force transfer mechanisms. Linkage 856 can be operably attached to the motive element via one or more linkages and/or connectors. Retraction assembly 800 can be of similar construction and arrangement to similar components described in applicant's co-pending International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018.
In some embodiments, imaging system 10 comprises a patient interface unit 200. Patient interface unit 200 can comprise a single housing, containing both rotation assembly 500 and retraction assembly 800. Alternatively or additionally, patient interface unit 200 can comprise two or more housings, such as a separate housing for each of rotation assembly 500 and retraction assembly 800. In some embodiments, connector 150, service loop 185, retraction element 850, and connector 852 are housed in a single housing, configured to operably attach to both rotation assembly 500 and retraction assembly 800 (e.g. such as when rotation assembly 500 and retraction assembly 800 are housed within a single housing).
Console 50 comprises an imaging assembly 300, a user interface 55, processor 52, and one or more algorithms 51. Imaging assembly 300 can be configured to provide light to optical assembly 115 (e.g. via optical core 110) and collect light from optical assembly 115 (e.g. via optical core 110). Imaging assembly 300 can include a light source 310. Light source 310 can comprise one or more light sources, such as one or more light sources configured to provide one or more wavelengths of light to optical assembly 115 via optical core 110. Light source 310 is configured to provide light to optical assembly 115 (via optical core 110) such that image data can be collected comprising cross-sectional, longitudinal and/or volumetric information related to a patient site or implanted device being imaged. Light source 310 can be configured to provide light such that the image data collected includes characteristics of tissue within the patient site being imaged, such as to quantify, qualify or otherwise provide information related to a patient disease or disorder present within the patient site being imaged. Light source 310 can be configured to deliver broadband light and have a center wavelength in the range from 350 nm to 2500 nm, from 800 nm to 1700 nm, from 1280 nm to 1310 nm, or approximately 1300 nm (e.g. light delivered with a sweep range from 1250 nm to 1350 nm). Light source 310 bandwidth can be selected to achieve a desired resolution, which can vary according to the needs of the intended use of imaging system 10. In some embodiments, bandwidths are about 5% to 15% of the center wavelength, which allows resolutions of between 20 μm and 5 μm. Light source 310 can be configured to deliver light at a power level meeting ANSI Class 1 (“eye safe”) limits, though higher power levels can be employed. In some embodiments, light source 310 delivers light in the 1.3 μm band at a power level of approximately 20 mW. Tissue light scattering is reduced as the center wavelength of delivered light increases, however water absorption increases. Light source 310 can deliver light at a wavelength approximating 1300 nm to balance these two effects. Light source 310 can be configured to deliver shorter wavelength light (e.g. approximately 800 nm light) to traverse patient sites to be imaged including large amounts of fluid. Alternatively or additionally, light source 310 can be configured to deliver longer wavelengths of light (e.g. approximately 1700 nm light), such as to reduce a high level of scattering within a patient site to be imaged. In some embodiments, light source 310 comprises a tunable light source (e.g. light source 310 emits a single wavelength that changes repetitively over time), and/or a broad-band light source. Light source 310 can comprise a single spatial mode light source or a multimode light source (e.g. a multimode light source with spatial filtering). Imaging assembly 300 can be of similar construction and arrangement to similar components described in applicant's co-pending U.S. Provisional Patent Application Ser. No. 62/732,114, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2018.
Console 50 can comprise one or more algorithms, such as algorithm 51 shown, which can be configured to adjust (e.g. automatically and/or semi-automatically adjust) one or more operational parameters of imaging system 10, such as an operational parameter of console 50, imaging probe 100 and/or a delivery catheter 80. Console 50 can further comprise a processing assembly, processor 52, configured to execute algorithm 51, and/or perform any type of data processing, such as digital signal processing, described herebelow in reference to
Imaging system 10 can comprise one or more interconnect cables, bus 58 shown. Bus 58 can operably connect rotation assembly 500 to console 50, retraction assembly 800 to console 50, and or rotation assembly 500 to retraction assembly 800 (e.g. by connecting patient interface unit 200 to console 50). Bus 58 can comprise one or more optical transmission fibers, electrical transmission cables, fluid conduits, and combinations of one or more of these. In some embodiments, bus 58 comprises at least an optical transmission fiber that optically couples rotation assembly 500 to imaging assembly 300 of console 50. Additionally or alternatively, bus 58 comprises at least power and/or data transmission cables that transfer power and/or motive information to retraction assembly 800.
User interface 55 can comprise an output 56 and an input 57. Output 56 can comprise one or more outputs selected from the group consisting of: a screen; an indicator light; a tactile transducer such as a vibrational transducer; a speaker; an output signal, such as a wireless signal, to be received by an external device; and combinations of these. Input 57 can comprise an input selected from the group consisting of: a button; two or more buttons; a touch screen; a mouse; an input signal, such as a wireless signal received from an external device; and combinations of these. In some embodiments, output 56 and/or input 57 are integrated into patient interface unit 200, and/or either or both of rotational assembly 500 and retraction assembly 800.
Second imaging device 15 can comprise an imaging device such as one or more imaging devices selected from the group consisting of: an X-ray; a fluoroscope such as a single plane or biplane fluoroscope; a CT Scanner; an MRI; a PET Scanner; an ultrasound imager; and combinations of one or more of these. In some embodiments, second imaging device 15 comprises a device configured to perform rotational angiography.
Treatment device 16 can comprise an occlusion treatment or other treatment device selected from the group consisting of: a balloon catheter constructed and arranged to dilate a stenosis or other narrowing of a blood vessel; a drug eluting balloon; an aspiration catheter; a sonolysis device; an atherectomy device; a thrombus removal device such as a stent retriever device; a Trevo™ stentriever; a Solitaire™ stentriever; a Revive™ stentriever; an Eric™ stentriever; a Lazarus™ stentriever; a stent delivery catheter; a microbraid implant; an embolization system; a WEB™ embolization system; a Luna™ embolization system; a Medina™ embolization system; and combinations of one or more of these. In some embodiments, imaging probe 100 is configured to collect data related to treatment device 16 (e.g. treatment device 16 location, orientation and/or other configuration data), after treatment device 16 has been inserted into the patient.
Injector 20 can comprise a power injector, syringe pump, peristaltic pump or other fluid delivery device configured to inject a contrast agent, such as radiopaque contrast, and/or other fluids. In some embodiments, injector 20 is configured to deliver contrast and/or other fluid (e.g. contrast, saline and/or Dextran). In some embodiments, injector 20 delivers fluid in a flushing procedure as described herebelow. In some embodiments, injector 20 delivers contrast or other fluid through a delivery catheter 80 with an ID of between 5 Fr and 9 Fr, a delivery catheter 80 with an ID of between 0.53″ to 0.70″, or a delivery catheter 80 with an ID between 0.0165″ and 0.027″. In some embodiments, contrast or other fluid is delivered through a delivery catheter as small as 4 Fr (e.g. for distal injections). In some embodiments, injector 20 delivers contrast and/or other fluid through the lumen of one or more delivery catheters 80, while one or more smaller delivery catheters 80 also reside within the lumen. In some embodiments, injector 20 is configured to deliver two dissimilar fluids simultaneously and/or sequentially, such as a first fluid delivered from a first reservoir and comprising a first concentration of contrast, and a second fluid from a second reservoir and comprising less or no contrast.
Injectate 21 can comprise fluid selected from the group consisting of: optically transparent material; saline; visualizable material; contrast; Dextran; an ultrasonically reflective material; a magnetic material; and combinations thereof. Injectate 21 can comprise contrast and saline. Injectate 21 can comprise at least 20% contrast. During collection of image data, a flushing procedure can be performed, such as by delivering one or more fluids, injectate 21 (e.g. as propelled by injector 20 or other fluid delivery device), to remove blood or other somewhat opaque material (hereinafter non-transparent material) proximate optical assembly 115 (e.g. to remove non-transparent material between optical assembly 115 and a delivery catheter and/or non-transparent material between optical assembly 115 and a vessel wall), such as to allow light distributed from optical assembly 115 to reach and reflectively return from all tissue and other objects to be imaged. In these flushing embodiments, injectate 21 can comprise an optically transparent material, such as saline. Injectate 21 can comprise one or more visualizable materials, as described herebelow.
As an alternative or in addition to its use in a flushing procedure, injectate 21 can comprise material configured to be viewed by second imaging device 15, such as when injectate 21 comprises a contrast material configured to be viewed by a second imaging device 15 comprising a fluoroscope or other X-ray device; an ultrasonically reflective material configured to be viewed by a second imaging device 15 comprising an ultrasound imager; and/or a magnetic material configured to be viewed by a second imaging device 15 comprising an Mill.
Implant 31 can comprise an implant (e.g. a temporary or chronic implant) for treating one or more of a vascular occlusion or an aneurysm. In some embodiments, implant 31 comprises one or more implants selected from the group consisting of: a flow diverter; a Pipeline™ flow diverter; a Surpass™ flow diverter; an embolization coil; a stent; a Wingspan™ stent; a covered stent; an aneurysm treatment implant; and combinations of one or more of these.
Implant delivery device 30 can comprise a catheter or other tool used to deliver implant 31, such as when implant 31 comprises a self-expanding or balloon expandable portion. In some embodiments, imaging system 10 comprises imaging probe 100, one or more implants 31 and/or one or more implant delivery devices 30. In some embodiments, imaging probe 100 is configured to collect data related to implant 31 and/or implant delivery device 30 (e.g. implant 31 and/or implant delivery device 30 anatomical location, orientation and/or other configuration data), after implant 31 and/or implant delivery device 30 has been inserted into the patient.
In some embodiments, one or more system components, such as console 50, delivery catheter 80, imaging probe 100, patient interface unit 200, rotation assembly 500, retraction assembly 800, treatment device 16, injector 20, and/or implant delivery device 30, further comprise one or more functional elements (“functional element” herein), such as functional elements 59, 89, 199, 299, 599, 899, 99a, 99b, and/or 99c, respectively, shown. Each functional element can comprise at least two functional elements. Each functional element can comprise one or more elements selected from the group consisting of: sensor; transducer; and combinations thereof. The functional element can comprise a sensor configured to produce a signal. The functional element can comprise a sensor selected from the group consisting of: a physiologic sensor; a pressure sensor; a strain gauge; a position sensor; a GPS sensor; an accelerometer; a temperature sensor; a magnetic sensor; a chemical sensor; a biochemical sensor; a protein sensor; a flow sensor such as an ultrasonic flow sensor; a gas detecting sensor such as an ultrasonic bubble detector; a sound sensor such as an ultrasound sensor; and combinations thereof. The sensor can comprise a physiologic sensor selected from the group consisting of: a pressure sensor such as a blood pressure sensor; a blood gas sensor; a flow sensor such as a blood flow sensor; a temperature sensor such as a blood or other tissue temperature sensor; and combinations thereof. The sensor can comprise a position sensor configured to produce a signal related to a vessel path geometry (e.g. a 2D or 3D vessel path geometry). The sensor can comprise a magnetic sensor. The sensor can comprise a flow sensor. The system can further comprise an algorithm configured to process the signal produced by the sensor-based functional element. Each functional element can comprise one or more transducers. Each functional element can comprise one or more transducers selected from the group consisting of: a heating element such as a heating element configured to deliver sufficient heat to ablate tissue; a cooling element such as a cooling element configured to deliver cryogenic energy to ablate tissue; a sound transducer such as an ultrasound transducer; a vibrational transducer; and combinations thereof.
In some embodiments, imaging probe 100 comprises a “bubble-handling” mechanism, fluid pressurization element (FPE) 1500 shown, such as for preventing or at least reducing the presence of bubbles proximate optical assembly 115, as described in detail herein. FPE 1500 can be configured to generate a pressure differential within a volume of gel 180 and/or otherwise to increase the pressure of one or more volumes of gel 180. FPE 1500 can comprise a distal end that is placed relatively proximate the proximal end of optical assembly 115. In some embodiments, FPE 1500 is configured to increase the pressure of and/or generate a pressure differential within a volume of gel 180 that is proximate optical assembly 115. Additionally or alternatively, FPE 1500 can generate a flow of gel 180 (e.g. a flow of gel 180 including one or more bubbles, such as to move the bubbles away from optical assembly 115). FPE 1500 can comprise a projection extending from optical core 110 that increases the pressure of gel 180 when FPE 1500 is rotated (via rotation of optical core 110). Alternatively or additionally, FPE 1500 can comprise a pump, pressurized vessel, and/or other pressurization source (“pump” herein) that is fluidly attached to one or more lumens (e.g. lumen 1205 of shaft 120), such as to increase the pressure of gel 180 (e.g. intermittently and on demand by system 10).
As shown in
In some embodiments, one or more bubbles B may become trapped distal to high-pressure area HP, however FPE 1500 is constructed and arranged to manipulate gel 180 proximate optical assembly 115, such as to prevent any bubbles B from becoming trapped proximate assembly 115 (e.g. the distally trapped bubbles B do not migrate toward optical assembly 115). Additionally or alternatively, the increased pressure of high-pressure area HP can cause a reduction in size of any existing bubbles B proximate optical assembly 115 (e.g. a compression of any bubbles B within high pressure area HP) and/or the increased pressure can prevent new bubbles B from forming. In some embodiments, high pressure area HP generated by FPE 1500 comprises a pressure of at least 3.6 psi (e.g. at least approximately 0.25 atmospheres), such as a pressure of at least 5 psi, at least 10 psi, at least 15 psi, at least 20 psi, at least 30 psi, and/or at least 40 psi. In some embodiments, FPE 1500 generates pressure in area HP of at least 75 psi, at least 100 psi, at least 125 psi, and/or at least 150 psi. In some embodiments, high pressure-area HP comprises a pressure at least 5 psi above low pressure area LP, such as at least 10 psi, at least 20 psi, and/or at least 30 psi greater than the pressure of low pressure area LP. In some embodiments, each bubble B undergoes a compression of two or three times (i.e. ½ or ⅓ the original size) under the high-pressure conditions of high-pressure area HP.
In some embodiments, gel 180 comprises a low viscosity fluid, such as a shear thinning fluid with a low starting viscosity, such that bubbles B have a lower likelihood of formation. For example, gel 180 can comprise a viscosity of 1000 centipoise or less. Additionally or alternatively, gel 180 can comprise a high surface tension, such as a surface tension of at least 40 dynes/cm, again such that bubbles B have a lower likelihood of formation.
In some embodiments, gel 180 is pressurized by a pump (e.g. intermittently pressurized to a pressure at or above atmospheric pressure), such as when lumen 1205 is pressurized, such as via a pump fluidly connected to lumen 1205 and located within console 50 or patient interface unit 200 (e.g. FPE 1500 comprises this pump that is fluidly attached but external to lumen 1205). In some embodiments, gel 180 is pressurized by an external source, and FPE 1500 is constructed and arranged to generate (e.g. when rotated) a pressure differential within gel 180 in addition to the pressure applied by the separate pump. Intermittent pressurization (e.g. via an external pump or via rotation of FPE 1500) can provide numerous advantages, such as to prevent the increase of dissolved gasses in gel 180 that would result from constant applied pressure, as described herein.
In some embodiments, FPE 1500 comprises a helical projection radially extending from optical core 110 that is configured to increase pressure of gel 180 and/or generate a pressure differential within gel 180 when optical core 110 is rotated, such as is described herebelow in reference to
In some embodiments, FPE 1500 is configured to operate intermittently, such as to intermittently increase the pressure of gel 180 such as to intermittently generate a pressure differential within gel 180. For example, FPE 1500 can comprise one or more radially extending projections from optical core 110 that are configured to generate a pressure differential in gel 180 only when optical core 110 is rotating, such as is described herebelow in reference to
Referring now to
In some embodiments, FPE 1500S comprises a helical coil, such as a spring or other wound wire, affixed along a portion of the length of optical core 110 (e.g. surrounding core 110). FPE 1500S can be adhered, such as via glue or another adhesive, to optical core 110. In some embodiments, FPE 1500S is molded on and/or with core 110, formed into (e.g. such as via a material removal process) core 110, fused onto core 110, and/or otherwise manufactured with or adhered to core 110. In some embodiments, FPE 1500S comprises a material selected from the group consisting of: metal; plastic; stainless steel; nickel-titanium alloy; nylon; polyether ether ketone (PEEK); polyimide; and combinations of these. In some embodiments, FPE 1500S can be formed directly onto optical core 110, such as using a deposition technique and/or 3D printing technique. In some embodiments, a selectively curable material is applied to optical core 110 and cured in a spiral pattern to form FPE 1500S. For example, a high-strength UV-cured adhesive can be applied to the surface of optical core 110 and selectively cured using a rotating, focused UV beam. In some embodiments, FPE 1500S can comprise a material selected to minimize deformation of FPE 1500S while the pressure gradient is applied. For example, during rotation a pressure gradient occurs across the length of FPE 1500S, such that to prevent deformation, a shorter FPE 1500S would require a stiffer material than a longer FPE 1500S configured to produce the same pressure gradient.
FPE 1500S comprises a radial height, height H1, which is the distance from the surface of optical core 110 to the outer edge of FPE 1500S. Optical core 110 comprises a diameter D1. Lumen 1205 of shaft 120 comprises an internal diameter D2. In some embodiments, diameters D1 and D2 vary along the length of probe 100, and the following dimensions relate to a segment of probe 100, such as a distal segment shown in
In some embodiments, gel 180 comprises a high viscosity, shear thinning fluid, such as is described hereabove in reference to
In some embodiments, FPE 1500S comprises a covering (not shown). The covering can comprise a sheath, such as a heat shrink tube, and/or a painted or sprayed on coating. The covering can be configured to improve the bonding of FPE 1500S to optical core 110, and/or to control the dimensions of FPE 1500S (e.g. to hold FPE 1500S tightly to optical core 110, such as to limit unwanted variations in height H1). Additionally or alternatively, the covering can be configured to modify the surface properties of either or both of optical core 110 and FPE 1500S. In some embodiments, the covering comprises a thickness that does not significantly affect the fluid propulsion and/or other fluid pressurization (“fluid pressurization” herein) performance of FPE 1500S. Alternatively or additionally, FPE 1500S can be constructed and arranged such that the dimensions C1, H1, and D1 are optimal after the application of the covering.
In some embodiments, the pressurization of gel 180 within lumen 1205 caused by the rotation of FPE 1500S exerts a functional torsional sheer force on the inner wall of lumen 1205. Shaft 120 can comprise a torsional resistance greater than the functional torsional sheer force exerted by gel 180. In some embodiments, gel 180 exerts a torque of approximately 0.004 N-cm, and shaft 120 comprises a torsional resistance of at least 0.01 N-cm, such as 0.03 N-cm. Additionally or alternatively, FPE 1500S can exert a “wind-up” stress on optical core 110 as optical core 110 is rotated, driving FPE 1500S within gel 180. Optical core 110 can be constructed and arranged to not be adversely affected by (e.g. not break or otherwise fail) the sheer stress induced by the rotation of core 110 and FPE 1500, within gel 180 as well as the shear stress induced by the pullback motion within gel 180. In some embodiments, the additional windup stress on optical core 110 caused by FPE 1500S functions as a NURD reduction mechanism, similar to NURD reduction caused by gel 180, as described in applicant's co-pending International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018.
Referring additionally to
Referring now to
In some embodiments, FPE 1500 comprises two fluid propulsion elements, such as FPE 1500S1 and 1500S2, as shown in
Referring now to
Referring now to
Referring now to
FPE 1500S can be configured to generate both a motive force and a pressure gradient within gel 180, causing one or more resulting scenarios, as illustrated in
As shown in
In some embodiments, as shown in
Referring now to
Joint 125 can comprise at least the distal portion of tube 121 and at least the proximal portion of window 130. The distal portion of tube 121 can comprise a tapered portion, taper 1211. Taper 1211 can be configured such that the outer diameter of tube 121 decreases from the proximal end of taper 1211 to the distal end of taper 1211. Tube 121 comprises a lumen 1215 therethrough. An elongate segment, tube 123, is partially inserted into lumen 1215 of tube 121. Tube 123 can comprise an outer diameter approximately equal to the diameter of lumen 1215. In some embodiments, tube 123 comprises an outer diameter slightly greater than the diameter of lumen 1215 (e.g. such that tube 123 can be press fit into lumen 1215), or tube 123 comprises a diameter equal to or slightly smaller than the diameter of lumen 1215 (e.g. such as to provide space for an adhesive between tube 125 and tube 121). Tube 123 comprises a lumen 1235 therethrough. In some embodiments, lumen 1235 comprises a diameter greater than the outer diameter of optical core 110 (e.g. such that optical core 110 can be slidingly positioned therethrough). Additionally or alternatively, lumen 1235 can comprise a diameter (e.g. tube 123 comprises an inner diameter) that is less than the outer diameter of FPE 1500S, such that FPE 1500S cannot translate proximally beyond tube 123 (e.g. translation of FPE 1500S proximally causes FPE 1500S to contact the end of tube 123, preventing FPE 1500S from entering lumen 1235).
Joint 125 can further comprise an overtube 122, configured to surround at least the distal portion of tube 121 and at least a portion of tube 123 (e.g. at least a portion of tube 123 extending distally from lumen 1215). Overtube 122 can comprise a “heat shrink” material, (e.g. a material configured to contract when heat is applied). In these embodiments, overtube 122 can comprise a first diameter (e.g. a pre-shrunk diameter) equal to or greater than the outer diameter of tube 121, such that tube 121 can be slidingly received within overtube 122. After overtube 122 is positioned relative to tubes 121 and 123, heat can be applied such that overtube 122 shrinks and conforms to the outer profile of tubes 121 and 123. Additionally or alternatively, overtube 122 can comprise an elastic material. In some embodiments, overtube 122 can comprise an elastic material and an inner diameter less than or equal to the outer diameter of tube 123. In these embodiments, overtube 122 can be positioned about tubes 121 and 123 by stretching overtube 122 to slidingly receive tubes 121 and 123, such that overtube 122 contracts after positioning to conform to the outer profile of tubes 121 and 123. In some embodiments, overtube 122 can be “rolled” onto tubes 121 and 123, such that overtube 122 both stretches and conforms as it is rolled over tubes 121 and 123. Overtube 122 can comprise PET.
The proximal portion of window 130 can comprise an inward radial projection 1302. Radial projection 1302 can comprise an inner diameter constructed and arranged to match the outer diameter of tubes 123 and 122 (e.g. the outer diameter of tube 122 compressed about tube 123). In some embodiments, window 130 does not include radial projection 1302, and the inner diameter of window 130 is constructed and arranged to match the outer diameter of tubes 123 and 122. In some embodiments, the proximal portion of window 130 slidingly receives the distal portion of tubes 122 and 123. The proximal portion of window 130 can further slidingly receive at least a distal portion of taper 1211 of tube 121. Window 130 can be fixedly attached to tubes 121, 122, and/or 123 via compression and/or an adhesive. In some embodiments, the outer surface of overtube 122 can be prepared (e.g. mechanically or chemically prepared) for adhesion to window 130, for example via a chemical primer. In some embodiments, the proximal end of window 130 is “shrunk” onto tubes 121, 122, and/or 123 to provide a compression fit. In some embodiments, window 130 comprises a material configured to contract when under tension (e.g. when window 130 is pulled, intentionally or unintentionally away from tube 121), such that window 130 compresses onto tubes 121, 122, and/or 123, strengthening joint 125 when under tension. In these embodiments, tubes 121, 122, and/or 123 can comprise a lower modulus than window 130, such that window 130 compresses more under equal tension than one or more of tubes 121, 122, and/or 123.
In some embodiments, joint 125 comprises a maximum outer diameter of no more than 0.02″, such as no more than 0.0175″, such as less than or equal to 0.0155″. In some embodiments, joint 125 comprises a tensile strength of at least 2 N, such as at least 2.6 N, such as at least 5.5 N, such as at least 6 N. In some embodiments, the distal portion of imaging probe 100 (including joint 125 and at least a distal segment of tube 121, for example the distal 30 cm of imaging probe 100) comprises a minimum bend radius of no more than 5 mm, such as no more than 4 mm, no more than 3 mm, or no more than 2.5 mm.
In some embodiments, optical core 110 can comprise two or more layers (e.g. two or more concentric layers), such as a core 1105, which can be surrounded by one or more layers of cladding, cladding 1106.
Referring now to
Referring now to
The above-described embodiments should be understood to serve only as illustrative examples; further embodiments are envisaged. Any feature described herein in relation to any one embodiment may be used alone, or in combination with other features described, and may also be used in combination with one or more features of any other of the embodiments, or any combination of any other of the embodiments. Furthermore, equivalents and modifications not described above may also be employed without departing from the scope of the inventive concepts, which is defined in the accompanying claims.
This application claims benefit to U.S. Provisional Application Ser. No. 62/840,450, titled “Imaging Probe with Fluid Pressurization Element”, filed Apr. 30, 2019, the content of which is incorporated by reference in its entirety. This application claims benefit to U.S. Provisional Application Ser. No. 63/017,258, titled “Imaging System”, filed Apr. 29, 2020, the content of which is incorporated by reference in its entirety. This application claims benefit to U.S. Provisional Application Ser. No. 62/850,945, titled “OCT-Guided Treatment of a Patient”, filed May 21, 2019, the content of which is incorporated by reference in its entirety. This application claims benefit to U.S. Provisional Application Ser. No. 62/906,353, titled “OCT-Guided Treatment of a Patient”, filed Sep. 26, 2019, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/148,355, titled “Micro-Optic Probes for Neurology”, filed Apr. 16, 2015, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/322,182, titled “Micro-Optic Probes for Neurology”, filed Apr. 13, 2016, the content of which is incorporated by reference in its entirety. This application is related to International PCT Patent Application Serial Number PCT/US2016/027764, titled “Micro-Optic Probes for Neurology” filed Apr. 15, 2016, Publication Number WO 2016/168605, published Oct. 20, 2016, the content of which is incorporated by reference in its entirety. This application is related to U.S. patent application Ser. No. 15/566,041, titled “Micro-Optic Probes for Neurology”, filed Oct. 12, 2017, United States Publication Number 2018-0125372, published May 10, 2018, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/212,173, titled “Imaging System Includes Imaging Probe and Delivery Devices”, filed Aug. 31, 2015, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/368,387, titled “Imaging System Includes Imaging Probe and Delivery Devices”, filed Jul. 29, 2016, the content of which is incorporated by reference in its entirety. This application is related to International PCT Patent Application Serial Number PCT/US2016/049415, titled “Imaging System Includes Imaging Probe and Delivery Devices”, filed Aug. 30, 2016, Publication Number WO 2017/040484, published Mar. 9, 2017, the content of which is incorporated by reference in its entirety. This application is related to U.S. patent application Ser. No. 15/751,570, titled “Imaging System Includes Imaging Probe and Delivery Devices”, filed Feb. 9, 2018, U.S. Pat. No. 10,631,718, issued Apr. 28, 2020, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/591,403, titled “Imaging System”, filed Nov. 28, 2017, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/671,142, titled “Imaging System”, filed May 14, 2018, the content of which is incorporated by reference in its entirety. This application is related to International PCT Patent Application Serial Number PCT/US2018/062766, titled “Imaging System”, filed Nov. 28, 2018, Publication Number WO 2019/108598, published Jun. 6, 2019, the content of which is incorporated by reference in its entirety. This application is related to U.S. Provisional Application Ser. No. 62/732,114, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2018, the content of which is incorporated by reference in its entirety. This application is related to International PCT Patent Application Serial Number PCT/US2019/051447, titled “Imaging System with Optical Pathway”, filed Sep. 17, 2019, Publication Number WO 2020/0611001, published Mar. 26, 2020, the content of which is incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/030616 | 4/30/2020 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2020/223433 | 11/5/2020 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4460989 | Russell | Jul 1984 | A |
| 4554929 | Samson et al. | Nov 1985 | A |
| 4566330 | Fujii et al. | Jan 1986 | A |
| 4583184 | Murase | Apr 1986 | A |
| 4588982 | Goodwin | May 1986 | A |
| 4594895 | Fujii | Jun 1986 | A |
| 4597292 | Fujii et al. | Jul 1986 | A |
| 4646748 | Fujii et al. | Mar 1987 | A |
| 4753248 | Engler et al. | Jun 1988 | A |
| 4951677 | Crowley et al. | Aug 1990 | A |
| 4957482 | Shiber | Sep 1990 | A |
| 4961427 | Namekawa et al. | Oct 1990 | A |
| 4983169 | Furukawa | Jan 1991 | A |
| 5002059 | Crowley et al. | Mar 1991 | A |
| 5039193 | Snow et al. | Aug 1991 | A |
| 5058587 | Kohno et al. | Oct 1991 | A |
| 5118405 | Kaneko et al. | Jun 1992 | A |
| 5127405 | Alcala et al. | Jul 1992 | A |
| 5143075 | Ishizuka | Sep 1992 | A |
| 5151603 | Nakamura | Sep 1992 | A |
| 5152277 | Honda et al. | Oct 1992 | A |
| 5158086 | Brown et al. | Oct 1992 | A |
| 5212671 | Fujii et al. | May 1993 | A |
| 5219335 | Willard et al. | Jun 1993 | A |
| 5321501 | Swanson et al. | Jun 1994 | A |
| 5331309 | Sakai | Jul 1994 | A |
| 5383467 | Auer et al. | Jan 1995 | A |
| 5443781 | Saab | Aug 1995 | A |
| 5456245 | Bornhop et al. | Oct 1995 | A |
| 5459570 | Swanson et al. | Oct 1995 | A |
| 5502567 | Pokrowsky et al. | Mar 1996 | A |
| 5554139 | Okajima | Sep 1996 | A |
| 5568314 | Omori et al. | Oct 1996 | A |
| 5568503 | Omori | Oct 1996 | A |
| 5588081 | Takahashi | Dec 1996 | A |
| 5644427 | Omori et al. | Jul 1997 | A |
| 5647359 | Kohno et al. | Jul 1997 | A |
| 5649897 | Nakamura et al. | Jul 1997 | A |
| 5689316 | Hattori et al. | Nov 1997 | A |
| 5738100 | Yagami et al. | Apr 1998 | A |
| 5745163 | Nakamura et al. | Apr 1998 | A |
| 5774175 | Hattori | Jun 1998 | A |
| 5774261 | Omori et al. | Jun 1998 | A |
| 5793341 | Omori et al. | Aug 1998 | A |
| 5818399 | Omori et al. | Oct 1998 | A |
| 5827242 | Follmer et al. | Oct 1998 | A |
| 5860923 | Lenker et al. | Jan 1999 | A |
| 5976017 | Omori et al. | Nov 1999 | A |
| 5999591 | Kobayashi et al. | Dec 1999 | A |
| 6011580 | Hattori et al. | Jan 2000 | A |
| 6011809 | Tosaka | Jan 2000 | A |
| 6019507 | Takaki | Feb 2000 | A |
| 6019737 | Murata | Feb 2000 | A |
| 6033383 | Ginsburg | Mar 2000 | A |
| 6036682 | Lange et al. | Mar 2000 | A |
| 6052613 | Takaki | Apr 2000 | A |
| 6064684 | Yoon et al. | May 2000 | A |
| 6069698 | Ozawa et al. | May 2000 | A |
| 6115058 | Omori et al. | Sep 2000 | A |
| 6134003 | Tearney et al. | Oct 2000 | A |
| 6160826 | Swanson et al. | Dec 2000 | A |
| 6165127 | Crowley | Dec 2000 | A |
| 6191862 | Swanson et al. | Feb 2001 | B1 |
| 6208887 | Clarke | Mar 2001 | B1 |
| 6217828 | Bretscher et al. | Apr 2001 | B1 |
| 6283632 | Takaki | Sep 2001 | B1 |
| 6296608 | Daniels et al. | Oct 2001 | B1 |
| 6309358 | Okubo | Oct 2001 | B1 |
| 6341036 | Tearney et al. | Jan 2002 | B1 |
| 6364841 | White et al. | Apr 2002 | B1 |
| 6383209 | Crowley | May 2002 | B1 |
| 6445939 | Swanson et al. | Sep 2002 | B1 |
| 6449500 | Asai et al. | Sep 2002 | B1 |
| 6471656 | Shalman et al. | Oct 2002 | B1 |
| 6485413 | Boppart et al. | Nov 2002 | B1 |
| 6485482 | Belef | Nov 2002 | B1 |
| 6520959 | Iwahashi et al. | Feb 2003 | B1 |
| 6530921 | Maki | Mar 2003 | B1 |
| 6547757 | Kranz et al. | Apr 2003 | B1 |
| 6549687 | Kochergin et al. | Apr 2003 | B1 |
| 6552796 | Magnin et al. | Apr 2003 | B2 |
| 6564087 | Pitris et al. | May 2003 | B1 |
| 6565514 | Svanerudh et al. | May 2003 | B2 |
| 6570659 | Schmitt | May 2003 | B2 |
| 6570893 | Libatique et al. | May 2003 | B1 |
| 6572553 | Crowley | Jun 2003 | B2 |
| 6577391 | Faupel et al. | Jun 2003 | B1 |
| 6579286 | Maki et al. | Jun 2003 | B1 |
| 6589233 | Maki | Jul 2003 | B1 |
| 6601459 | Jenni | Aug 2003 | B1 |
| 6607526 | Maki | Aug 2003 | B1 |
| 6615072 | Izatt et al. | Sep 2003 | B1 |
| 6654630 | Zuluaga et al. | Nov 2003 | B2 |
| 6658278 | Gruhl | Dec 2003 | B2 |
| 6758818 | Pantages et al. | Jul 2004 | B2 |
| 6879851 | McNamara et al. | Apr 2005 | B2 |
| 6881194 | Miyata et al. | Apr 2005 | B2 |
| 6891984 | Petersen et al. | May 2005 | B2 |
| 6904197 | Bhagavatula et al. | Jun 2005 | B2 |
| 6904199 | Zuluaga | Jun 2005 | B2 |
| 6916286 | Kazakevich | Jul 2005 | B2 |
| 6925320 | Gruhl | Aug 2005 | B2 |
| 6940885 | Cheng et al. | Sep 2005 | B1 |
| 7003184 | Ronnekleiv et al. | Feb 2006 | B2 |
| 7016024 | Bridge et al. | Mar 2006 | B2 |
| 7022118 | Ariura et al. | Apr 2006 | B2 |
| 7024025 | Sathyanarayana | Apr 2006 | B2 |
| 7029436 | Izuka et al. | Apr 2006 | B2 |
| 7099358 | Chong | Aug 2006 | B1 |
| 7134994 | Alpert et al. | Nov 2006 | B2 |
| 7139120 | Sugiya | Nov 2006 | B2 |
| 7155272 | Yamaguchi et al. | Dec 2006 | B2 |
| 7167300 | Fermann et al. | Jan 2007 | B2 |
| 7180600 | Horii et al. | Feb 2007 | B2 |
| 7231243 | Tearney et al. | Jun 2007 | B2 |
| 7241286 | Atlas | Jul 2007 | B2 |
| 7365859 | Yun et al. | Apr 2008 | B2 |
| 7366376 | Shishkov et al. | Apr 2008 | B2 |
| 7382949 | Bouma et al. | Jun 2008 | B2 |
| 7450980 | Kawanishi | Nov 2008 | B2 |
| 7551293 | Yelin et al. | Jun 2009 | B2 |
| 7567349 | Tearney et al. | Jul 2009 | B2 |
| 7625366 | Atlas | Dec 2009 | B2 |
| 7682089 | Rohlen | Mar 2010 | B2 |
| 7691061 | Hirota | Apr 2010 | B2 |
| 7711413 | Feldman et al. | May 2010 | B2 |
| 7724786 | Bouma et al. | May 2010 | B2 |
| 7733497 | Yun et al. | Jun 2010 | B2 |
| 7738941 | Hirota | Jun 2010 | B2 |
| 7740408 | Irisawa | Jun 2010 | B2 |
| 7742173 | Yun et al. | Jun 2010 | B2 |
| 7761139 | Tearney et al. | Jul 2010 | B2 |
| 7783337 | Feldman et al. | Aug 2010 | B2 |
| 7794230 | Lakin et al. | Sep 2010 | B2 |
| 7803141 | Epstein et al. | Sep 2010 | B2 |
| 7812961 | Yamaguchi | Oct 2010 | B2 |
| 7813609 | Petersen et al. | Oct 2010 | B2 |
| 7815632 | Hayakawa et al. | Oct 2010 | B2 |
| 7843572 | Tearney et al. | Nov 2010 | B2 |
| 7847949 | Tearney et al. | Dec 2010 | B2 |
| 7848791 | Schmitt et al. | Dec 2010 | B2 |
| 7867778 | Hayenga et al. | Jan 2011 | B2 |
| 7872759 | Tearney et al. | Jan 2011 | B2 |
| 7905838 | Hirota | Mar 2011 | B2 |
| 7911621 | Motaghiannezam et al. | Mar 2011 | B2 |
| 7916387 | Schmitt | Mar 2011 | B2 |
| 7920271 | Vakoc et al. | Apr 2011 | B2 |
| 7922650 | McWeeney et al. | Apr 2011 | B2 |
| 7926562 | Poitzsch et al. | Apr 2011 | B2 |
| 7935060 | Schmitt et al. | May 2011 | B2 |
| 7940397 | Masuda | May 2011 | B2 |
| 7952718 | Li et al. | May 2011 | B2 |
| 7969578 | Yun et al. | Jun 2011 | B2 |
| 7982879 | Desjardins et al. | Jul 2011 | B2 |
| 8018598 | Cense et al. | Sep 2011 | B2 |
| 8029446 | Horiike et al. | Oct 2011 | B2 |
| 8029447 | Kanz et al. | Oct 2011 | B2 |
| 8032200 | Tearney et al. | Oct 2011 | B2 |
| 8040524 | Ozawa | Oct 2011 | B2 |
| 8047996 | Goodnow et al. | Nov 2011 | B2 |
| 8049900 | Kemp et al. | Nov 2011 | B2 |
| 8052605 | Muller et al. | Nov 2011 | B2 |
| 8055107 | Masuda | Nov 2011 | B2 |
| 8081316 | De Boer et al. | Dec 2011 | B2 |
| 8094319 | Onimura | Jan 2012 | B2 |
| 8100833 | Hirota | Jan 2012 | B2 |
| 8108032 | Onimura et al. | Jan 2012 | B2 |
| 8116605 | Petersen et al. | Feb 2012 | B2 |
| 8125648 | Milner et al. | Feb 2012 | B2 |
| 8149418 | Tearney et al. | Apr 2012 | B2 |
| 8157741 | Hirota | Apr 2012 | B2 |
| 8157742 | Taylor | Apr 2012 | B2 |
| 8174702 | Tearney et al. | May 2012 | B2 |
| 8206372 | Larson et al. | Jun 2012 | B2 |
| 8206377 | Petroff | Jun 2012 | B2 |
| 8208995 | Tearney et al. | Jun 2012 | B2 |
| 8231516 | Maschke | Jul 2012 | B2 |
| 8241196 | Scibona | Aug 2012 | B2 |
| 8289522 | Tearney et al. | Oct 2012 | B2 |
| RE43875 | Shishkov et al. | Dec 2012 | E |
| 8322932 | Irisawa | Dec 2012 | B2 |
| 8325419 | Schmitt | Dec 2012 | B2 |
| 8337379 | Fletcher et al. | Dec 2012 | B2 |
| 8339592 | Hlavinka et al. | Dec 2012 | B2 |
| 8346348 | Onimura | Jan 2013 | B2 |
| 8351665 | Tearney et al. | Jan 2013 | B2 |
| 8355138 | Yun et al. | Jan 2013 | B2 |
| 8384907 | Tearney et al. | Feb 2013 | B2 |
| 8384909 | Yun et al. | Feb 2013 | B2 |
| 8412312 | Judell et al. | Apr 2013 | B2 |
| 8414496 | Goodnow et al. | Apr 2013 | B2 |
| 8449439 | Fletcher et al. | May 2013 | B2 |
| 8449468 | Petersen et al. | May 2013 | B2 |
| 8452371 | Feldman et al. | May 2013 | B2 |
| 8473037 | Irisawa | Jun 2013 | B2 |
| 8473073 | Vardiman | Jun 2013 | B2 |
| 8478384 | Schmitt et al. | Jul 2013 | B2 |
| 8478387 | Xu | Jul 2013 | B2 |
| 8493567 | Inoue | Jul 2013 | B2 |
| 8501015 | Fletcher et al. | Aug 2013 | B2 |
| 8503844 | Petersen et al. | Aug 2013 | B2 |
| 8531676 | Condit et al. | Sep 2013 | B2 |
| 8535210 | Kolenbrander et al. | Sep 2013 | B2 |
| 8556820 | Alpert et al. | Oct 2013 | B2 |
| 8559012 | Tearney et al. | Oct 2013 | B2 |
| 8581643 | Schmitt | Nov 2013 | B1 |
| 8582109 | Schmitt | Nov 2013 | B1 |
| 8582619 | Adler | Nov 2013 | B2 |
| 8582934 | Adler et al. | Nov 2013 | B2 |
| 8585592 | Luevano et al. | Nov 2013 | B2 |
| 8593619 | Colice et al. | Nov 2013 | B2 |
| 8593641 | Kemp et al. | Nov 2013 | B2 |
| 8618032 | Kurita | Dec 2013 | B2 |
| 8626453 | Myoujou et al. | Jan 2014 | B2 |
| 8636659 | Alpert et al. | Jan 2014 | B2 |
| 8676013 | Bouma et al. | Mar 2014 | B2 |
| 8676299 | Schmitt et al. | Mar 2014 | B2 |
| 8687201 | Adler | Apr 2014 | B2 |
| 8705046 | Yun et al. | Apr 2014 | B2 |
| 8712506 | Courtney et al. | Apr 2014 | B2 |
| 8753281 | Schmitt et al. | Jun 2014 | B2 |
| 8760663 | Tearney et al. | Jun 2014 | B2 |
| 8761469 | Kemp et al. | Jun 2014 | B2 |
| 8786336 | Schmitt | Jul 2014 | B1 |
| 8804126 | Tearney et al. | Aug 2014 | B2 |
| 8808186 | Fruland et al. | Aug 2014 | B2 |
| 8810901 | Huber et al. | Aug 2014 | B2 |
| 8825142 | Suehara | Sep 2014 | B2 |
| 8827926 | Kinoshita et al. | Sep 2014 | B2 |
| 8831321 | Elbasiony | Sep 2014 | B1 |
| 8868159 | Onimura | Oct 2014 | B2 |
| 8885171 | Watanabe et al. | Nov 2014 | B2 |
| 8896838 | Tearney et al. | Nov 2014 | B2 |
| 8902941 | Schmitt | Dec 2014 | B2 |
| 8909324 | Furuichi | Dec 2014 | B2 |
| 8911357 | Omori | Dec 2014 | B2 |
| 8926590 | Petroff | Jan 2015 | B2 |
| 8928889 | Tearney et al. | Jan 2015 | B2 |
| 8945526 | Akitsu et al. | Feb 2015 | B2 |
| 8948228 | Adler | Feb 2015 | B2 |
| 8948613 | Schmitt et al. | Feb 2015 | B2 |
| 8953911 | Xu et al. | Feb 2015 | B1 |
| 8983582 | Webler | Mar 2015 | B2 |
| 8989849 | Milner et al. | Mar 2015 | B2 |
| 8994803 | Kaneko | Mar 2015 | B2 |
| 8996099 | Feldman et al. | Mar 2015 | B2 |
| 8998797 | Omori | Apr 2015 | B2 |
| 9007696 | Petersen et al. | Apr 2015 | B2 |
| 9033890 | Furuichi | May 2015 | B2 |
| 9036966 | Bhagavatula et al. | May 2015 | B2 |
| 9039626 | Courtney | May 2015 | B2 |
| 9050238 | Nour et al. | Jun 2015 | B2 |
| 9060689 | Tearney et al. | Jun 2015 | B2 |
| 9069396 | Adler et al. | Jun 2015 | B2 |
| 9076202 | Courtney et al. | Jul 2015 | B2 |
| 9081148 | Tearney et al. | Jul 2015 | B2 |
| 9084532 | Horiike | Jul 2015 | B2 |
| 9087368 | Tearney et al. | Jul 2015 | B2 |
| 9091524 | Adler et al. | Jul 2015 | B2 |
| 9101298 | Hossack et al. | Aug 2015 | B2 |
| 9107682 | Scheller et al. | Aug 2015 | B2 |
| 9107687 | Kinoshita et al. | Aug 2015 | B2 |
| 9121926 | Nair et al. | Sep 2015 | B2 |
| 9131850 | Liu et al. | Sep 2015 | B2 |
| 9138147 | Schmitt et al. | Sep 2015 | B2 |
| 9164240 | Schmitt et al. | Oct 2015 | B2 |
| 9168003 | Suzuki et al. | Oct 2015 | B2 |
| 9173572 | Colice et al. | Nov 2015 | B2 |
| 9173591 | Elbasiony et al. | Nov 2015 | B2 |
| 9194690 | Bhagavatula et al. | Nov 2015 | B2 |
| 9207064 | Inoue | Dec 2015 | B2 |
| 9226660 | De Boer et al. | Jan 2016 | B2 |
| 9226665 | Tearney et al. | Jan 2016 | B2 |
| 9254102 | Tearney et al. | Feb 2016 | B2 |
| 9289127 | Mitsuhashi et al. | Mar 2016 | B2 |
| 9289582 | Suehara | Mar 2016 | B2 |
| 9295450 | Furuichi et al. | Mar 2016 | B2 |
| 9295455 | Karino et al. | Mar 2016 | B2 |
| 9301687 | Kemp | Apr 2016 | B2 |
| 9304121 | Tearney et al. | Apr 2016 | B2 |
| 9322639 | Watanabe et al. | Apr 2016 | B2 |
| 9326789 | Fruland et al. | May 2016 | B2 |
| 9330092 | Vakoc et al. | May 2016 | B2 |
| 9339173 | McWeeney et al. | May 2016 | B2 |
| 9339348 | Davies et al. | May 2016 | B2 |
| 9345864 | Suehara | May 2016 | B2 |
| 9347765 | Kemp et al. | May 2016 | B2 |
| 9351698 | Dascal et al. | May 2016 | B2 |
| 9357923 | Courtney et al. | Jun 2016 | B2 |
| 9375148 | Senoo | Jun 2016 | B2 |
| 9375158 | Vakoc et al. | Jun 2016 | B2 |
| 9375164 | Tolkowsky et al. | Jun 2016 | B2 |
| 9377290 | Yun et al. | Jun 2016 | B2 |
| 9404731 | Adler et al. | Aug 2016 | B2 |
| 9408539 | Tearney et al. | Aug 2016 | B2 |
| 9417052 | Adler | Aug 2016 | B2 |
| 9427173 | Sirohey et al. | Aug 2016 | B2 |
| 9435736 | Kolenbrander et al. | Sep 2016 | B2 |
| 9435956 | Xu et al. | Sep 2016 | B1 |
| 9439570 | Vertikov | Sep 2016 | B2 |
| 9441948 | Vakoc et al. | Sep 2016 | B2 |
| 9462950 | Xu | Oct 2016 | B2 |
| 9464883 | Swanson et al. | Oct 2016 | B2 |
| 9488464 | Schmitt | Nov 2016 | B1 |
| 9507074 | Zhu et al. | Nov 2016 | B2 |
| 9513276 | Tearney et al. | Dec 2016 | B2 |
| 9526424 | Judell et al. | Dec 2016 | B2 |
| 9566752 | Hartkorn | Feb 2017 | B2 |
| 9572495 | Schmitt et al. | Feb 2017 | B2 |
| 9572496 | Furuichi et al. | Feb 2017 | B2 |
| 9574870 | Yamazaki et al. | Feb 2017 | B2 |
| 9591967 | Nishiyama et al. | Mar 2017 | B2 |
| 9605942 | Staloff | Mar 2017 | B2 |
| 9610064 | Adler et al. | Apr 2017 | B2 |
| 9615771 | Furuichi et al. | Apr 2017 | B2 |
| 9622706 | Dick et al. | Apr 2017 | B2 |
| 9638862 | Bhagavatula et al. | May 2017 | B2 |
| 9642531 | Tearney et al. | May 2017 | B2 |
| 9645322 | Murashima et al. | May 2017 | B2 |
| 9646377 | Tearney et al. | May 2017 | B2 |
| 9659375 | Zagrodsky et al. | May 2017 | B2 |
| 9702687 | Schmitt | Jul 2017 | B2 |
| 9702762 | Friedman et al. | Jul 2017 | B2 |
| 9704240 | Lam et al. | Jul 2017 | B2 |
| 9710891 | Sakamoto | Jul 2017 | B2 |
| 9730613 | Stigall et al. | Aug 2017 | B2 |
| 9763623 | Tearney et al. | Sep 2017 | B2 |
| 9778020 | Tumlinson | Oct 2017 | B2 |
| 9788790 | Black et al. | Oct 2017 | B2 |
| 9808303 | Ryba et al. | Nov 2017 | B2 |
| 9812846 | Yun et al. | Nov 2017 | B2 |
| 9833221 | Hutchins et al. | Dec 2017 | B2 |
| 9836835 | Furuichi et al. | Dec 2017 | B2 |
| 9843159 | Cable et al. | Dec 2017 | B2 |
| 9855020 | Nair et al. | Jan 2018 | B2 |
| 9858387 | Lavi et al. | Jan 2018 | B2 |
| 9864140 | Adler et al. | Jan 2018 | B2 |
| 9872665 | Okubo et al. | Jan 2018 | B2 |
| 9891044 | Tu et al. | Feb 2018 | B2 |
| 9897538 | Tearney et al. | Feb 2018 | B2 |
| 9907527 | Dascal et al. | Mar 2018 | B2 |
| 9907536 | Courtney et al. | Mar 2018 | B2 |
| 9933244 | Krol et al. | Apr 2018 | B2 |
| 9940723 | Gopinath et al. | Apr 2018 | B2 |
| 9943233 | Lavi et al. | Apr 2018 | B2 |
| 9962127 | Wang et al. | May 2018 | B2 |
| 9980648 | Itoh et al. | May 2018 | B2 |
| 9983356 | Schmitt et al. | May 2018 | B2 |
| 9986916 | Köhler et al. | Jun 2018 | B2 |
| 9986938 | Tu et al. | Jun 2018 | B2 |
| 9989945 | Adler et al. | Jun 2018 | B2 |
| 9996921 | Ambwani et al. | Jun 2018 | B2 |
| 10004400 | Nakamoto et al. | Jun 2018 | B2 |
| 10004863 | Vazales et al. | Jun 2018 | B2 |
| 10006753 | Schmitt et al. | Jun 2018 | B2 |
| 10028725 | Petroff | Jul 2018 | B2 |
| 10089755 | Griffin et al. | Oct 2018 | B2 |
| 10092188 | Jaffer et al. | Oct 2018 | B2 |
| 10109058 | Ambwani et al. | Oct 2018 | B2 |
| 10124153 | Feig et al. | Nov 2018 | B2 |
| 10140712 | Ambwani | Nov 2018 | B2 |
| 10162114 | Bhagavatula et al. | Dec 2018 | B2 |
| 10172582 | Dascal et al. | Jan 2019 | B2 |
| 10186056 | Senzig et al. | Jan 2019 | B2 |
| 10207124 | Shimizu et al. | Feb 2019 | B2 |
| 10213109 | Itoh et al. | Feb 2019 | B2 |
| 10213186 | Inoue et al. | Feb 2019 | B2 |
| 10219780 | Castella et al. | Mar 2019 | B2 |
| 10222956 | Gopinath et al. | Mar 2019 | B2 |
| 10231712 | Ebbini et al. | Mar 2019 | B2 |
| 10238349 | Furuichi et al. | Mar 2019 | B2 |
| 10238816 | Matsubara et al. | Mar 2019 | B2 |
| 10261223 | Tearney et al. | Apr 2019 | B2 |
| 10271818 | Kobayashi | Apr 2019 | B2 |
| 10285568 | Tearney et al. | May 2019 | B2 |
| 10327726 | Dascal et al. | Jun 2019 | B2 |
| 10331099 | Adler et al. | Jun 2019 | B2 |
| 10335039 | Xu | Jul 2019 | B2 |
| 10338795 | Gopinath et al. | Jul 2019 | B2 |
| 10342502 | Dascal et al. | Jul 2019 | B2 |
| 10387013 | Jamello | Aug 2019 | B2 |
| 10453190 | Griffin | Oct 2019 | B2 |
| 10453191 | Shalev et al. | Oct 2019 | B2 |
| 10453196 | Ambwani | Oct 2019 | B2 |
| 10463254 | Tearney et al. | Nov 2019 | B2 |
| 10499813 | Adler | Dec 2019 | B2 |
| 10529093 | Griffin et al. | Jan 2020 | B2 |
| 10551251 | Friedman et al. | Feb 2020 | B2 |
| 10568831 | Mendenhall et al. | Feb 2020 | B2 |
| 10593037 | Gopinath | Mar 2020 | B2 |
| 10631718 | Petroff et al. | Apr 2020 | B2 |
| 10631754 | Gopinath | Apr 2020 | B2 |
| 10646198 | Peterson et al. | May 2020 | B2 |
| 10648918 | Schmitt | May 2020 | B2 |
| 10687777 | Dascal et al. | Jun 2020 | B2 |
| 10713786 | Ambwani et al. | Jul 2020 | B2 |
| 10729376 | Courtney | Aug 2020 | B2 |
| 10792012 | Hutchins et al. | Oct 2020 | B2 |
| 10806421 | Keller | Oct 2020 | B2 |
| 10878572 | Gopinath et al. | Dec 2020 | B2 |
| 10902599 | Ambwani et al. | Jan 2021 | B2 |
| 11051761 | Courtney et al. | Jul 2021 | B2 |
| 11058385 | Kunio | Jul 2021 | B2 |
| 11064873 | Petroff et al. | Jul 2021 | B2 |
| 11278206 | Petroff et al. | Mar 2022 | B2 |
| 11298110 | Mansour et al. | Apr 2022 | B2 |
| RE49218 | Courtney et al. | Sep 2022 | E |
| 11583172 | Petroff et al. | Feb 2023 | B2 |
| 11684242 | Petroff et al. | Jun 2023 | B2 |
| 20020041724 | Ronnekleiv et al. | Apr 2002 | A1 |
| 20020045811 | Kittrell et al. | Apr 2002 | A1 |
| 20020072880 | Svanerudh et al. | Jun 2002 | A1 |
| 20020099289 | Crowley | Jul 2002 | A1 |
| 20020131049 | Schmitt | Sep 2002 | A1 |
| 20020151799 | Pantages et al. | Oct 2002 | A1 |
| 20020151823 | Miyata et al. | Oct 2002 | A1 |
| 20020163622 | Magnin et al. | Nov 2002 | A1 |
| 20020183601 | Tearney et al. | Dec 2002 | A1 |
| 20020183622 | Zuluaga et al. | Dec 2002 | A1 |
| 20020188204 | McNamara et al. | Dec 2002 | A1 |
| 20020198457 | Tearney et al. | Dec 2002 | A1 |
| 20030004417 | Ariura et al. | Jan 2003 | A1 |
| 20030013952 | Iizuka et al. | Jan 2003 | A1 |
| 20030032863 | Kazakevich | Feb 2003 | A1 |
| 20030073909 | Gruhl | Apr 2003 | A1 |
| 20030081875 | Kochergin et al. | May 2003 | A1 |
| 20030147551 | Sathyanarayana | Aug 2003 | A1 |
| 20030165291 | Bhagavatula et al. | Sep 2003 | A1 |
| 20030216621 | Alpert et al. | Nov 2003 | A1 |
| 20040017961 | Petersen et al. | Jan 2004 | A1 |
| 20040034290 | Zuluaga | Feb 2004 | A1 |
| 20040082861 | Gruhl | Apr 2004 | A1 |
| 20040092913 | Hennings et al. | May 2004 | A1 |
| 20040136053 | Sugiya | Jul 2004 | A1 |
| 20040215166 | Atlas | Oct 2004 | A1 |
| 20050004453 | Tearney et al. | Jan 2005 | A1 |
| 20050038406 | Epstein et al. | Feb 2005 | A1 |
| 20050101870 | Yamaguchi et al. | May 2005 | A1 |
| 20050128488 | Yelin et al. | Jun 2005 | A1 |
| 20050163426 | Fermann et al. | Jul 2005 | A1 |
| 20050168751 | Horii et al. | Aug 2005 | A1 |
| 20050187422 | Maschke | Aug 2005 | A1 |
| 20050201662 | Petersen et al. | Sep 2005 | A1 |
| 20050221277 | Kawanishi | Oct 2005 | A1 |
| 20050259242 | Bridge et al. | Nov 2005 | A1 |
| 20050272975 | McWeeney et al. | Dec 2005 | A1 |
| 20050288583 | Hirota | Dec 2005 | A1 |
| 20060039004 | De Boer et al. | Feb 2006 | A1 |
| 20060055936 | Yun et al. | Mar 2006 | A1 |
| 20060058622 | Tearney et al. | Mar 2006 | A1 |
| 20060067620 | Shishkov et al. | Mar 2006 | A1 |
| 20060091566 | Yang et al. | May 2006 | A1 |
| 20060093276 | Bouma et al. | May 2006 | A1 |
| 20060095065 | Tanimura et al. | May 2006 | A1 |
| 20060135870 | Webler | Jun 2006 | A1 |
| 20060166176 | Lakin et al. | Jul 2006 | A1 |
| 20060227333 | Tearney et al. | Oct 2006 | A1 |
| 20060241484 | Horiike et al. | Oct 2006 | A1 |
| 20060241493 | Feldman et al. | Oct 2006 | A1 |
| 20060241503 | Schmitt et al. | Oct 2006 | A1 |
| 20060244973 | Yun et al. | Nov 2006 | A1 |
| 20060247743 | Hayakawa et al. | Nov 2006 | A1 |
| 20060279742 | Tearney et al. | Dec 2006 | A1 |
| 20070012886 | Tearney et al. | Jan 2007 | A1 |
| 20070015969 | Feldman et al. | Jan 2007 | A1 |
| 20070035743 | Vakoc et al. | Feb 2007 | A1 |
| 20070038040 | Cense et al. | Feb 2007 | A1 |
| 20070038274 | Ishii et al. | Feb 2007 | A1 |
| 20070060822 | Alpert et al. | Mar 2007 | A1 |
| 20070073162 | Tearney et al. | Mar 2007 | A1 |
| 20070081236 | Tearney et al. | Apr 2007 | A1 |
| 20070106155 | Goodnow et al. | May 2007 | A1 |
| 20070121196 | Tearney et al. | May 2007 | A1 |
| 20070201033 | Desjardins et al. | Aug 2007 | A1 |
| 20070229801 | Tearney et al. | Oct 2007 | A1 |
| 20070232890 | Hirota | Oct 2007 | A1 |
| 20070232891 | Hirota | Oct 2007 | A1 |
| 20070232892 | Hirota | Oct 2007 | A1 |
| 20070232893 | Tanioka | Oct 2007 | A1 |
| 20070233396 | Tearney et al. | Oct 2007 | A1 |
| 20070236700 | Yun et al. | Oct 2007 | A1 |
| 20070244391 | Hirota | Oct 2007 | A1 |
| 20070260198 | Atlas | Nov 2007 | A1 |
| 20070268456 | Ohbayshi et al. | Nov 2007 | A1 |
| 20080002211 | Park et al. | Jan 2008 | A1 |
| 20080004530 | Feldman et al. | Jan 2008 | A1 |
| 20080007734 | Park et al. | Jan 2008 | A1 |
| 20080019908 | Akitsu et al. | Jan 2008 | A1 |
| 20080021275 | Tearney et al. | Jan 2008 | A1 |
| 20080045394 | Fletcher et al. | Feb 2008 | A1 |
| 20080049232 | Vakoc et al. | Feb 2008 | A1 |
| 20080161696 | Schmitt et al. | Jul 2008 | A1 |
| 20080165366 | Schmitt | Jul 2008 | A1 |
| 20080177139 | Courtney et al. | Jul 2008 | A1 |
| 20080181263 | Bouma et al. | Jul 2008 | A1 |
| 20080205739 | Hayenga et al. | Aug 2008 | A1 |
| 20080208227 | Kadykowski et al. | Aug 2008 | A1 |
| 20080225301 | Yamaguchi | Sep 2008 | A1 |
| 20080262346 | Assis et al. | Oct 2008 | A1 |
| 20080269572 | Kanz et al. | Oct 2008 | A1 |
| 20080291463 | Milner et al. | Nov 2008 | A1 |
| 20080297806 | Motaghiannezam et al. | Dec 2008 | A1 |
| 20090018393 | Dick et al. | Jan 2009 | A1 |
| 20090027689 | Yun et al. | Jan 2009 | A1 |
| 20090036782 | Vakoc et al. | Feb 2009 | A1 |
| 20090043191 | Castella et al. | Feb 2009 | A1 |
| 20090046295 | Kemp et al. | Feb 2009 | A1 |
| 20090046980 | Rohlen | Feb 2009 | A1 |
| 20090073454 | Ozawa | Mar 2009 | A1 |
| 20090073455 | Onimura | Mar 2009 | A1 |
| 20090093980 | Kemp et al. | Apr 2009 | A1 |
| 20090122320 | Petersen et al. | May 2009 | A1 |
| 20090131801 | Suter et al. | May 2009 | A1 |
| 20090135429 | Masuda | May 2009 | A1 |
| 20090143686 | Onimura et al. | Jun 2009 | A1 |
| 20090182246 | Kinoshita et al. | Jul 2009 | A1 |
| 20090192519 | Omori | Jul 2009 | A1 |
| 20090196477 | Cense et al. | Aug 2009 | A1 |
| 20090196554 | Irisawa | Aug 2009 | A1 |
| 20090251704 | Masuda | Oct 2009 | A1 |
| 20090261240 | Watanabe et al. | Oct 2009 | A1 |
| 20090262361 | Tanioka et al. | Oct 2009 | A1 |
| 20090281423 | Sirohey et al. | Nov 2009 | A1 |
| 20090283258 | Poitzsch et al. | Nov 2009 | A1 |
| 20090299195 | Muller et al. | Dec 2009 | A1 |
| 20090306520 | Schmitt et al. | Dec 2009 | A1 |
| 20090323076 | Li et al. | Dec 2009 | A1 |
| 20100019189 | Kurita | Jan 2010 | A1 |
| 20100042084 | Nariyuki et al. | Feb 2010 | A1 |
| 20100073682 | Inoue | Mar 2010 | A1 |
| 20100076320 | Petersen et al. | Mar 2010 | A1 |
| 20100094127 | Xu | Apr 2010 | A1 |
| 20100110414 | Colice et al. | May 2010 | A1 |
| 20100130872 | Irisawa | May 2010 | A1 |
| 20100157309 | Tearney et al. | Jun 2010 | A1 |
| 20100158339 | Omori | Jun 2010 | A1 |
| 20100160134 | Scibona | Jun 2010 | A1 |
| 20100160780 | Swan et al. | Jun 2010 | A1 |
| 20100168587 | Feldman et al. | Jul 2010 | A1 |
| 20100220334 | Condit et al. | Sep 2010 | A1 |
| 20100241154 | Larson et al. | Sep 2010 | A1 |
| 20100249588 | Knight | Sep 2010 | A1 |
| 20100249601 | Courtney | Sep 2010 | A1 |
| 20100253949 | Adler et al. | Oct 2010 | A1 |
| 20100298908 | Vardiman | Nov 2010 | A1 |
| 20100305452 | Black et al. | Dec 2010 | A1 |
| 20100309477 | Yun et al. | Dec 2010 | A1 |
| 20110007315 | Petersen et al. | Jan 2011 | A1 |
| 20110009741 | Matthews et al. | Jan 2011 | A1 |
| 20110019182 | Hlavinka et al. | Jan 2011 | A1 |
| 20110058178 | Tearney et al. | Mar 2011 | A1 |
| 20110071404 | Schmitt et al. | Mar 2011 | A1 |
| 20110071405 | Judell et al. | Mar 2011 | A1 |
| 20110092823 | Tearney et al. | Apr 2011 | A1 |
| 20110101207 | Schmitt | May 2011 | A1 |
| 20110143905 | Kolenbrander et al. | Jun 2011 | A1 |
| 20110144504 | Tearney et al. | Jun 2011 | A1 |
| 20110149296 | Tearney et al. | Jun 2011 | A1 |
| 20110151980 | Petroff | Jun 2011 | A1 |
| 20110152771 | Milner et al. | Jun 2011 | A1 |
| 20110157686 | Huber et al. | Jun 2011 | A1 |
| 20110172511 | Petersen et al. | Jul 2011 | A1 |
| 20110178398 | Tearney et al. | Jul 2011 | A1 |
| 20110178413 | Schmitt et al. | Jul 2011 | A1 |
| 20110190586 | Kemp | Aug 2011 | A1 |
| 20110196217 | Myoujou et al. | Aug 2011 | A1 |
| 20110201924 | Tearney et al. | Aug 2011 | A1 |
| 20110216325 | Schmitt | Sep 2011 | A1 |
| 20110218403 | Tearney et al. | Sep 2011 | A1 |
| 20110224541 | Yun et al. | Sep 2011 | A1 |
| 20110228280 | Schmitt et al. | Sep 2011 | A1 |
| 20110237958 | Onimura | Sep 2011 | A1 |
| 20110245683 | Onimura | Oct 2011 | A1 |
| 20110245684 | Onimura | Oct 2011 | A1 |
| 20110257463 | Nour et al. | Oct 2011 | A1 |
| 20110261366 | Tearney et al. | Oct 2011 | A1 |
| 20110267340 | Kraus et al. | Nov 2011 | A1 |
| 20110270091 | Hossack et al. | Nov 2011 | A1 |
| 20110292400 | Fleming et al. | Dec 2011 | A1 |
| 20110299091 | Yun et al. | Dec 2011 | A1 |
| 20120002928 | Irisawa | Jan 2012 | A1 |
| 20120004506 | Tearney et al. | Jan 2012 | A1 |
| 20120007974 | Kaneko | Jan 2012 | A1 |
| 20120008146 | Tearney et al. | Jan 2012 | A1 |
| 20120013914 | Kemp et al. | Jan 2012 | A1 |
| 20120022360 | Kemp | Jan 2012 | A1 |
| 20120035454 | Tearney et al. | Feb 2012 | A1 |
| 20120053918 | Taylor | Mar 2012 | A1 |
| 20120057157 | Petersen et al. | Mar 2012 | A1 |
| 20120063570 | Furuichi et al. | Mar 2012 | A1 |
| 20120065517 | Goodnow et al. | Mar 2012 | A1 |
| 20120071736 | Luevano et al. | Mar 2012 | A1 |
| 20120123352 | Fruland et al. | May 2012 | A1 |
| 20120127476 | De Boer et al. | May 2012 | A1 |
| 20120135384 | Nakao | May 2012 | A1 |
| 20120170848 | Kemp et al. | Jul 2012 | A1 |
| 20120190974 | Suehara | Jul 2012 | A1 |
| 20120215091 | Suzuki et al. | Aug 2012 | A1 |
| 20120220836 | Alpert et al. | Aug 2012 | A1 |
| 20120226151 | Irisawa | Sep 2012 | A1 |
| 20120236883 | Adler | Sep 2012 | A1 |
| 20120238869 | Schmitt et al. | Sep 2012 | A1 |
| 20120243761 | Senzig et al. | Sep 2012 | A1 |
| 20120245459 | Senoo | Sep 2012 | A1 |
| 20120250028 | Schmitt et al. | Oct 2012 | A1 |
| 20120253114 | Kinoshita et al. | Oct 2012 | A1 |
| 20120253123 | Shimizu et al. | Oct 2012 | A1 |
| 20120253184 | Furuichi et al. | Oct 2012 | A1 |
| 20120253185 | Furuichi | Oct 2012 | A1 |
| 20120281237 | Tearney et al. | Nov 2012 | A1 |
| 20120310081 | Adler et al. | Dec 2012 | A1 |
| 20120330101 | Brennan et al. | Dec 2012 | A1 |
| 20130002843 | Horiike | Jan 2013 | A1 |
| 20130006104 | Mitsuhashi et al. | Jan 2013 | A1 |
| 20130006105 | Furuichi | Jan 2013 | A1 |
| 20130010303 | Petersen et al. | Jan 2013 | A1 |
| 20130012810 | Nakamoto et al. | Jan 2013 | A1 |
| 20130012811 | Schmitt et al. | Jan 2013 | A1 |
| 20130023760 | Liu et al. | Jan 2013 | A1 |
| 20130023761 | Petroff | Jan 2013 | A1 |
| 20130046190 | Davies et al. | Feb 2013 | A1 |
| 20130051728 | Petroff et al. | Feb 2013 | A1 |
| 20130072367 | Fletcher et al. | Mar 2013 | A1 |
| 20130072805 | Schmitt et al. | Mar 2013 | A1 |
| 20130079630 | Horiike | Mar 2013 | A1 |
| 20130079631 | Horiike et al. | Mar 2013 | A1 |
| 20130100455 | Tearney et al. | Apr 2013 | A1 |
| 20130107043 | Fletcher et al. | May 2013 | A1 |
| 20130116671 | Scheller et al. | May 2013 | A1 |
| 20130128274 | Yun et al. | May 2013 | A1 |
| 20130144165 | Ebbini et al. | Jun 2013 | A1 |
| 20130148106 | Tearney et al. | Jun 2013 | A1 |
| 20130176571 | Tearney et al. | Jul 2013 | A1 |
| 20130185023 | Vakoc et al. | Jul 2013 | A1 |
| 20130188850 | Tearney et al. | Jul 2013 | A1 |
| 20130215427 | Bouma et al. | Aug 2013 | A1 |
| 20130216114 | Courtney et al. | Aug 2013 | A1 |
| 20130217964 | Kumoyama et al. | Aug 2013 | A1 |
| 20130222813 | Watanabe et al. | Aug 2013 | A1 |
| 20130246034 | Sharma et al. | Sep 2013 | A1 |
| 20130266259 | Bhagavatula et al. | Oct 2013 | A1 |
| 20130278936 | Inoue | Oct 2013 | A1 |
| 20130281844 | Karino et al. | Oct 2013 | A1 |
| 20130303907 | Corl | Nov 2013 | A1 |
| 20130310698 | Judell et al. | Nov 2013 | A1 |
| 20130314716 | Tearney et al. | Nov 2013 | A1 |
| 20130331689 | Le et al. | Dec 2013 | A1 |
| 20140004045 | Mendenhall et al. | Jan 2014 | A1 |
| 20140005023 | Kolenbrander et al. | Jan 2014 | A1 |
| 20140005521 | Köhler et al. | Jan 2014 | A1 |
| 20140018669 | Xu | Jan 2014 | A1 |
| 20140024930 | Furuichi et al. | Jan 2014 | A1 |
| 20140024931 | Winston et al. | Jan 2014 | A1 |
| 20140031677 | Iftimia et al. | Jan 2014 | A1 |
| 20140031679 | Tashiro et al. | Jan 2014 | A1 |
| 20140036941 | Desmond | Feb 2014 | A1 |
| 20140063488 | Adler | Mar 2014 | A1 |
| 20140066706 | McWeeney et al. | Mar 2014 | A1 |
| 20140066756 | Sinclair et al. | Mar 2014 | A1 |
| 20140083970 | Kumar et al. | Mar 2014 | A1 |
| 20140088411 | Suehara et al. | Mar 2014 | A1 |
| 20140094697 | Petroff et al. | Apr 2014 | A1 |
| 20140100451 | Tolkowsky et al. | Apr 2014 | A1 |
| 20140114182 | Petersen et al. | Apr 2014 | A1 |
| 20140142427 | Petroff | May 2014 | A1 |
| 20140142432 | Hutchins et al. | May 2014 | A1 |
| 20140142436 | Hutchins et al. | May 2014 | A1 |
| 20140150782 | Vazales et al. | Jun 2014 | A1 |
| 20140177935 | Nair et al. | Jun 2014 | A1 |
| 20140180071 | Stigall et al. | Jun 2014 | A1 |
| 20140180083 | Hoseit | Jun 2014 | A1 |
| 20140180121 | Fong | Jun 2014 | A1 |
| 20140187929 | Schmitt et al. | Jul 2014 | A1 |
| 20140200867 | Lavi et al. | Jul 2014 | A1 |
| 20140206989 | Colice et al. | Jul 2014 | A1 |
| 20140207168 | Kawaura et al. | Jul 2014 | A1 |
| 20140218742 | Adler | Aug 2014 | A1 |
| 20140243876 | Suehara | Aug 2014 | A1 |
| 20140247454 | Bhagavatula et al. | Sep 2014 | A1 |
| 20140249407 | Adler et al. | Sep 2014 | A1 |
| 20140257087 | Elbasiony et al. | Sep 2014 | A1 |
| 20140267038 | Adler et al. | Sep 2014 | A1 |
| 20140268167 | Friedman et al. | Sep 2014 | A1 |
| 20140270436 | Dascal et al. | Sep 2014 | A1 |
| 20140270445 | Kemp | Sep 2014 | A1 |
| 20140275995 | Sheehan | Sep 2014 | A1 |
| 20140276020 | Hutchins et al. | Sep 2014 | A1 |
| 20140276108 | Vertikov | Sep 2014 | A1 |
| 20140277072 | Suehara | Sep 2014 | A1 |
| 20140301620 | Tearney et al. | Oct 2014 | A1 |
| 20140323877 | Courtney et al. | Oct 2014 | A1 |
| 20140346693 | Hartkorn | Nov 2014 | A1 |
| 20140371598 | Okubo et al. | Dec 2014 | A1 |
| 20140376000 | Swanson et al. | Dec 2014 | A1 |
| 20140378845 | Nadkarni | Dec 2014 | A1 |
| 20140379269 | Schmitt | Dec 2014 | A1 |
| 20150005615 | Inoue et al. | Jan 2015 | A1 |
| 20150005626 | Kaneko | Jan 2015 | A1 |
| 20150005627 | Itoh et al. | Jan 2015 | A1 |
| 20150005628 | Itoh et al. | Jan 2015 | A1 |
| 20150025369 | Bhagavatula et al. | Jan 2015 | A1 |
| 20150029513 | Tearney et al. | Jan 2015 | A1 |
| 20150036146 | Staloff | Feb 2015 | A1 |
| 20150049339 | Tearney et al. | Feb 2015 | A1 |
| 20150051485 | Itoh et al. | Feb 2015 | A1 |
| 20150057958 | Watanabe et al. | Feb 2015 | A1 |
| 20150077755 | Yun et al. | Mar 2015 | A1 |
| 20150080700 | Fruland et al. | Mar 2015 | A1 |
| 20150099968 | Jamello | Apr 2015 | A1 |
| 20150099975 | Lam et al. | Apr 2015 | A1 |
| 20150119707 | Petroff | Apr 2015 | A1 |
| 20150133773 | Jaffer et al. | May 2015 | A1 |
| 20150133776 | Hoffman | May 2015 | A1 |
| 20150133789 | Ariura et al. | May 2015 | A1 |
| 20150153157 | Schmitt et al. | Jun 2015 | A1 |
| 20150164331 | Burgess et al. | Jun 2015 | A1 |
| 20150164423 | Webler | Jun 2015 | A1 |
| 20150182192 | Kaneko | Jul 2015 | A1 |
| 20150190054 | Kaneko | Jul 2015 | A1 |
| 20150192405 | Schmitt | Jul 2015 | A1 |
| 20150196285 | Mori | Jul 2015 | A1 |
| 20150209526 | Matsubara et al. | Jul 2015 | A1 |
| 20150216415 | Uribe-Patarroyo et al. | Aug 2015 | A1 |
| 20150219854 | Bhagavatula et al. | Aug 2015 | A1 |
| 20150230775 | Kobayashi | Aug 2015 | A1 |
| 20150238084 | Tearney et al. | Aug 2015 | A1 |
| 20150238121 | Tu et al. | Aug 2015 | A1 |
| 20150245768 | Hasegawa et al. | Sep 2015 | A1 |
| 20150257704 | Courtney | Sep 2015 | A1 |
| 20150257850 | Sakamoto | Sep 2015 | A1 |
| 20150265152 | Feldman et al. | Sep 2015 | A1 |
| 20150265162 | Lavi et al. | Sep 2015 | A1 |
| 20150268039 | Tu et al. | Sep 2015 | A1 |
| 20150282737 | Tolkowsky et al. | Oct 2015 | A1 |
| 20150297373 | Schmitt et al. | Oct 2015 | A1 |
| 20150306361 | Feig et al. | Oct 2015 | A1 |
| 20150320317 | Furuichi et al. | Nov 2015 | A1 |
| 20150338646 | Innami | Nov 2015 | A1 |
| 20150366534 | Nair et al. | Dec 2015 | A1 |
| 20150366536 | Courtney et al. | Dec 2015 | A1 |
| 20150370229 | Adler et al. | Dec 2015 | A1 |
| 20150371382 | Furuichi et al. | Dec 2015 | A1 |
| 20160000406 | Petroff | Jan 2016 | A1 |
| 20160007838 | Ariura et al. | Jan 2016 | A1 |
| 20160008090 | Yokoi et al. | Jan 2016 | A1 |
| 20160015337 | Inoue et al. | Jan 2016 | A1 |
| 20160018211 | Adler et al. | Jan 2016 | A1 |
| 20160022208 | Gopinath | Jan 2016 | A1 |
| 20160022248 | Mori et al. | Jan 2016 | A1 |
| 20160070066 | Schmitt et al. | Mar 2016 | A1 |
| 20160073885 | Adler | Mar 2016 | A1 |
| 20160089203 | Shimizu et al. | Mar 2016 | A1 |
| 20160089547 | Shimizu et al. | Mar 2016 | A1 |
| 20160092749 | Sakamoto | Mar 2016 | A1 |
| 20160093049 | Kobayashi | Mar 2016 | A1 |
| 20160095577 | Itoh et al. | Apr 2016 | A1 |
| 20160113485 | Nishiyama et al. | Apr 2016 | A1 |
| 20160120408 | Bhagavatula et al. | May 2016 | A1 |
| 20160120492 | Honma et al. | May 2016 | A1 |
| 20160124134 | Zhu et al. | May 2016 | A1 |
| 20160153765 | Yamazaki et al. | Jun 2016 | A1 |
| 20160157803 | Keller | Jun 2016 | A1 |
| 20160166815 | Suehara | Jun 2016 | A1 |
| 20160171701 | Zagrodsky et al. | Jun 2016 | A1 |
| 20160171711 | Gopinath et al. | Jun 2016 | A1 |
| 20160174925 | Dascal et al. | Jun 2016 | A1 |
| 20160199017 | Shimizu et al. | Jul 2016 | A1 |
| 20160202417 | Bhagavatula et al. | Jul 2016 | A1 |
| 20160206208 | Yamamoto et al. | Jul 2016 | A1 |
| 20160206267 | Shimizu et al. | Jul 2016 | A1 |
| 20160206290 | Itoh et al. | Jul 2016 | A1 |
| 20160228071 | Wang et al. | Aug 2016 | A1 |
| 20160270766 | Kobayashi | Sep 2016 | A1 |
| 20160301189 | Cable et al. | Oct 2016 | A1 |
| 20160313507 | Adler et al. | Oct 2016 | A1 |
| 20160320170 | Yun et al. | Nov 2016 | A1 |
| 20160320564 | Murashima et al. | Nov 2016 | A1 |
| 20160335763 | Ambwani et al. | Nov 2016 | A1 |
| 20160335766 | Ambwani et al. | Nov 2016 | A1 |
| 20160338753 | Ryba et al. | Nov 2016 | A1 |
| 20160341538 | Tumlinson et al. | Nov 2016 | A1 |
| 20160349417 | Tearney et al. | Dec 2016 | A1 |
| 20160361018 | Courtney et al. | Dec 2016 | A1 |
| 20160370168 | Krol et al. | Dec 2016 | A1 |
| 20170014100 | Mori | Jan 2017 | A1 |
| 20170020392 | Xu | Jan 2017 | A1 |
| 20170024532 | Gopinath et al. | Jan 2017 | A1 |
| 20170024910 | Griffin et al. | Jan 2017 | A1 |
| 20170103520 | Gopinath et al. | Apr 2017 | A1 |
| 20170135663 | Dascal et al. | May 2017 | A1 |
| 20170140243 | Ambwani | May 2017 | A1 |
| 20170140531 | Dascal et al. | May 2017 | A1 |
| 20170140532 | Dascal et al. | May 2017 | A1 |
| 20170140560 | Kraus et al. | May 2017 | A1 |
| 20170143296 | Peterson et al. | May 2017 | A1 |
| 20170148161 | Griffin | May 2017 | A1 |
| 20170153439 | Horiike | Jun 2017 | A1 |
| 20170188831 | Adler et al. | Jul 2017 | A1 |
| 20170238809 | Tearney et al. | Aug 2017 | A1 |
| 20170261378 | Friedman et al. | Sep 2017 | A1 |
| 20170301084 | Gopinath | Oct 2017 | A1 |
| 20170309018 | Shalev et al. | Oct 2017 | A1 |
| 20170311806 | Comstock, II et al. | Nov 2017 | A1 |
| 20170325712 | Gopinath | Nov 2017 | A1 |
| 20170367581 | Tearney et al. | Dec 2017 | A1 |
| 20180003482 | Schmitt | Jan 2018 | A1 |
| 20180085095 | Hutchins et al. | Mar 2018 | A1 |
| 20180085170 | Gopinath | Mar 2018 | A1 |
| 20180125372 | Petroff et al. | May 2018 | A1 |
| 20180172424 | Comstock, II et al. | Jun 2018 | A1 |
| 20180177404 | Liu | Jun 2018 | A1 |
| 20180192957 | Schmitt et al. | Jul 2018 | A1 |
| 20180192983 | Dascal et al. | Jul 2018 | A1 |
| 20180225830 | Gopinath et al. | Aug 2018 | A1 |
| 20180226773 | Yun et al. | Aug 2018 | A1 |
| 20180275622 | Adler et al. | Sep 2018 | A1 |
| 20180293730 | Ambwani et al. | Oct 2018 | A1 |
| 20180306569 | Schmitt et al. | Oct 2018 | A1 |
| 20180344173 | Tu et al. | Dec 2018 | A1 |
| 20180344174 | Schmitt et al. | Dec 2018 | A9 |
| 20180353241 | Tu et al. | Dec 2018 | A1 |
| 20190029623 | Kunio | Jan 2019 | A1 |
| 20190035114 | Griffin et al. | Jan 2019 | A1 |
| 20190046161 | Mansour et al. | Feb 2019 | A1 |
| 20190096063 | Ambwani | Mar 2019 | A1 |
| 20190099237 | Booker et al. | Apr 2019 | A1 |
| 20190220980 | Ambwani et al. | Jul 2019 | A1 |
| 20190274528 | Petroff et al. | Sep 2019 | A1 |
| 20190307412 | Dascal et al. | Oct 2019 | A1 |
| 20190365480 | Gopinath et al. | Dec 2019 | A1 |
| 20190380594 | Schmitt et al. | Dec 2019 | A1 |
| 20200129067 | Krug et al. | Apr 2020 | A1 |
| 20200142575 | Gopinath et al. | May 2020 | A1 |
| 20200167923 | Gopinath | May 2020 | A1 |
| 20200288950 | Petroff et al. | Sep 2020 | A1 |
| 20200355557 | Friedman et al. | Nov 2020 | A1 |
| 20200397405 | Hutchins et al. | Dec 2020 | A1 |
| 20210004955 | Ambwani et al. | Jan 2021 | A1 |
| 20210045622 | Petroff et al. | Feb 2021 | A1 |
| 20210177282 | Ahmed et al. | Jun 2021 | A1 |
| 20210267442 | Petersen et al. | Sep 2021 | A1 |
| 20210318111 | Vakoc et al. | Oct 2021 | A1 |
| 20220061670 | Petroff et al. | Mar 2022 | A1 |
| 20220142464 | Petroff et al. | May 2022 | A1 |
| 20220218206 | Petroff et al. | Jul 2022 | A1 |
| 20220225880 | Mueller et al. | Jul 2022 | A1 |
| 20230000321 | Ughi et al. | Jan 2023 | A1 |
| 20230181016 | Ughi et al. | Jun 2023 | A1 |
| 20240000302 | Petroff et al. | Jan 2024 | A1 |
| 20240099564 | Petroff et al. | Mar 2024 | A1 |
| 20250000351 | Petroff et al. | Jan 2025 | A1 |
| Number | Date | Country |
|---|---|---|
| 2014200116 | Jan 2014 | AU |
| 1684624 | Oct 2005 | CN |
| 1780584 | May 2006 | CN |
| 101669028 | Mar 2010 | CN |
| 101773878 | Jul 2010 | CN |
| 203801215 | Sep 2014 | CN |
| 203801216 | Sep 2014 | CN |
| 203805643 | Sep 2014 | CN |
| 203805646 | Sep 2014 | CN |
| 104126111 | Oct 2014 | CN |
| 105019592 | Nov 2015 | CN |
| 204826364 | Dec 2015 | CN |
| 105662387 | Jun 2016 | CN |
| 106343957 | Jan 2017 | CN |
| 106570313 | Apr 2017 | CN |
| 106650029 | May 2017 | CN |
| 106805989 | Jun 2017 | CN |
| 106974622 | Jul 2017 | CN |
| 107115108 | Sep 2017 | CN |
| 107133959 | Sep 2017 | CN |
| 107233106 | Oct 2017 | CN |
| 107745346 | Mar 2018 | CN |
| 107978371 | May 2018 | CN |
| 108022650 | May 2018 | CN |
| 108038848 | May 2018 | CN |
| 207464715 | Jun 2018 | CN |
| 69738291 | Sep 2008 | DE |
| 112016005442 | Aug 2018 | DE |
| 112016005603 | Oct 2018 | DE |
| 0883793 | Dec 1998 | EP |
| 1685366 | Aug 2006 | EP |
| 2505129 | Oct 2012 | EP |
| 2803973 | Nov 2014 | EP |
| 2512077 | Sep 2014 | GB |
| 09168539 | Jun 1997 | JP |
| 2000503237 | Mar 2000 | JP |
| 2000097845 | Apr 2000 | JP |
| 2000097846 | Apr 2000 | JP |
| 2002214127 | Jul 2002 | JP |
| 2004158652 | Jun 2004 | JP |
| 2005224399 | Aug 2005 | JP |
| 2005230552 | Sep 2005 | JP |
| 2005533610 | Nov 2005 | JP |
| 2006271869 | Oct 2006 | JP |
| 2007268131 | Oct 2007 | JP |
| 2007271728 | Oct 2007 | JP |
| 20077267866 | Oct 2007 | JP |
| 2008510586 | Apr 2008 | JP |
| 2008514383 | May 2008 | JP |
| 2008523954 | Jul 2008 | JP |
| 2009072291 | Apr 2009 | JP |
| 2009276454 | Nov 2009 | JP |
| 4494203 | Jun 2010 | JP |
| 2010167029 | Aug 2010 | JP |
| 2010188138 | Sep 2010 | JP |
| 2010533052 | Oct 2010 | JP |
| 2011078550 | Apr 2011 | JP |
| 2012147860 | Aug 2012 | JP |
| 2012521852 | Sep 2012 | JP |
| 2012205661 | Oct 2012 | JP |
| 5093787 | Dec 2012 | JP |
| 2012254211 | Dec 2012 | JP |
| 2013500142 | Jan 2013 | JP |
| 2013506136 | Feb 2013 | JP |
| 2013521070 | Jun 2013 | JP |
| 5269809 | Aug 2013 | JP |
| 2013541392 | Nov 2013 | JP |
| 2014505496 | Mar 2014 | JP |
| 5474190 | Apr 2014 | JP |
| 2014145942 | Aug 2014 | JP |
| 2014180575 | Sep 2014 | JP |
| 2014526283 | Oct 2014 | JP |
| 5622796 | Nov 2014 | JP |
| 5635149 | Dec 2014 | JP |
| 5643315 | Dec 2014 | JP |
| 2015013217 | Jan 2015 | JP |
| 5689728 | Mar 2015 | JP |
| 2015062638 | Apr 2015 | JP |
| 5721721 | May 2015 | JP |
| 2015518393 | Jul 2015 | JP |
| 5778579 | Sep 2015 | JP |
| 2015164660 | Sep 2015 | JP |
| 5814860 | Nov 2015 | JP |
| 2015532717 | Nov 2015 | JP |
| 5856605 | Feb 2016 | JP |
| 2016038329 | Mar 2016 | JP |
| 2016508750 | Mar 2016 | JP |
| 2016512772 | May 2016 | JP |
| 2016514996 | May 2016 | JP |
| 5987025 | Sep 2016 | JP |
| 5997232 | Sep 2016 | JP |
| 2017524422 | Aug 2017 | JP |
| 2017532173 | Nov 2017 | JP |
| 2018020158 | Feb 2018 | JP |
| 2018507400 | Mar 2018 | JP |
| 2018516147 | Jun 2018 | JP |
| 2018527961 | Sep 2018 | JP |
| 2018527995 | Sep 2018 | JP |
| 2018191848 | Dec 2018 | JP |
| 2018192287 | Dec 2018 | JP |
| 2004010856 | Feb 2004 | WO |
| 2004096049 | Nov 2004 | WO |
| 2005047813 | May 2005 | WO |
| 2006022342 | Mar 2006 | WO |
| 2006024015 | Mar 2006 | WO |
| 2006037132 | Apr 2006 | WO |
| 2006068927 | Jun 2006 | WO |
| 2008134449 | Nov 2008 | WO |
| 2009009799 | Jan 2009 | WO |
| 2009009802 | Jan 2009 | WO |
| 2009010963 | Jan 2009 | WO |
| 2010095370 | Aug 2010 | WO |
| 2010113374 | Oct 2010 | WO |
| 2011038010 | Mar 2011 | WO |
| 2011059829 | May 2011 | WO |
| 2011064775 | Jun 2011 | WO |
| 2012002302 | Jan 2012 | WO |
| 2012061940 | May 2012 | WO |
| 2012064966 | May 2012 | WO |
| 2013033415 | Mar 2013 | WO |
| 2013126390 | Aug 2013 | WO |
| 2014055908 | Apr 2014 | WO |
| 2014142789 | Sep 2014 | WO |
| 2014142815 | Sep 2014 | WO |
| 2014147039 | Sep 2014 | WO |
| 2014149127 | Sep 2014 | WO |
| 2014163601 | Oct 2014 | WO |
| 2014175853 | Oct 2014 | WO |
| 2015022760 | Feb 2015 | WO |
| 2015044978 | Apr 2015 | WO |
| 2015044982 | Apr 2015 | WO |
| 2015044983 | Apr 2015 | WO |
| 2015044984 | Apr 2015 | WO |
| 2015074018 | May 2015 | WO |
| 2015103277 | Jul 2015 | WO |
| 2015136853 | Sep 2015 | WO |
| 2015141136 | Sep 2015 | WO |
| 2016039884 | Mar 2016 | WO |
| 2016168605 | Oct 2016 | WO |
| WO-2016168605 | Oct 2016 | WO |
| 2016187218 | Nov 2016 | WO |
| 2016187231 | Nov 2016 | WO |
| 2016210132 | Dec 2016 | WO |
| 2017011587 | Jan 2017 | WO |
| 2017019626 | Feb 2017 | WO |
| 2017019634 | Feb 2017 | WO |
| 2015044987 | Mar 2017 | WO |
| 2015045368 | Mar 2017 | WO |
| 2017040484 | Mar 2017 | WO |
| 2017097074 | Jun 2017 | WO |
| 2017189942 | Nov 2017 | WO |
| 2017200381 | Nov 2017 | WO |
| 2019108598 | Jun 2019 | WO |
| 2020061001 | Mar 2020 | WO |
| 2020237024 | Nov 2020 | WO |
| 2021222530 | Nov 2021 | WO |
| 2023133355 | Jul 2023 | WO |
| 2024081414 | Apr 2024 | WO |
| 2025076164 | Apr 2025 | WO |
| Entry |
|---|
| Japanese Office Action dated Sep. 26, 2023 issued in Japanese Application No. 2022164724, with English summary. |
| Japanese Office Action dated Mar. 19, 2024 issued in Japanese Application No. 2021564648, with English translation. |
| Japanese Office Action dated Feb. 21, 2023 issued in corresponding Japanese Application No. 2021-117103, with English summary. |
| Extended European Search Report dated Apr. 21, 2022 issued in corresponding European Application No. 19862071.8. |
| Tran et al. “In vivo endoscopic optical coherence tomography by use of a rotational microelectromechanical system probe”, Optics Letters, vol. 29 No. 11 (Jun. 1, 2004), p. 1236-1238. |
| Japanese Office Action dated Apr. 26, 2022 issued in corresponding Japanese Application No. 2021-068226, with English translation. |
| Abozenadah, H., et al. Consumer Chemistry: How Organic Chemistry Impacts Our Lives. CC BY-NC-SA. Available at: https://wou.edu/chemistry/courses/online-chemistry-textbooks/ch 105-consumer-chemistry/ (2017). |
| Athanasiou, L.S. et al. “Fully automated lumen segmentation of intracoronary optical coherence tomography images”, Medical Imaging 2017, vol. 10133, pp. 1013321-1-1013321-7. Downloaded from the internet on Mar. 6, 2017: http://proceedings.spiedigitallibrary.org/. |
| Berger, J.D. et al. “Widely tunable external cavity diode laser based on a MEMS electrostatic rotary actuator”, OSA/OFC 2001, pp. TuJ2-1-TuJ2-3. |
| BlazePhotonics. “NL-2.4-800 Highly nonlinear PCF” technical specification sheet. |
| Buus, J. et al. “Tunable Lasers in Optical Networks”, Journal Of Lightwave Technology, vol. 24, No. 1 (Jan. 2006), pp. 5-11. |
| Chang-Hasnain, C.J. “Tunable VCSEL”, IEEE Journal On Selected Topics In Quantum Electronics, vol. 6, No. 6 (Nov./Dec. 2000), pp. 978-987. |
| Chang-Hasnain, C.J., “Progress And Prospects Of Long-Wavelength VCSELs”, IEEE Optical Communications (Feb. 2003), pp. S30-S34. |
| Chinn, S.R. et al. “Optical coherence tomography using a frequency-tunable optical source”, Optics Letters, vol. 22, No. 5 (Mar. 1, 1997), pp. 340-342. |
| Chinese Notice of Allowance and Supplementary Search Report dated Jan. 13, 2021 issued in related Chinese Application No. 201680034490.4. |
| Chinese Office Action dated Aug. 28, 2019 issued in related Chinese Application No. 201680034490.4, with English translation. |
| Chinese Office Action dated Feb. 27, 2019 issued in related Chinese Application No. 201680034490.4, with English translation. |
| Chinese Office Action dated May 25, 2020 issued in related Chinese Application No. 201680034490.4, with English summary. |
| European Office Action dated Apr. 21, 2021 issued in corresponding European Application No. 16842796.1. |
| European Office Action dated Feb. 4, 2020 issued in related European Application No. 16780839.3. |
| Extended European Search Report dated Apr. 9, 2019 issued in related European Application No. 16842796.1. |
| Extended European Search Report dated Jan. 2, 2019 issued in related European Application No. 16780839.3. |
| Extended European Search Report dated Nov. 26, 2021 issued in corresponding European Application No. 18883166.3. |
| International Preliminary Report on Patentability dated Jun. 11, 2020 issued in related International Application No. PCT/US2018/062766. |
| International Preliminary Report on Patentability dated Mar. 15, 2018 issued in related International Application No. PCT/US2016/049415. |
| International Preliminary Report on Patentability dated Oct. 17, 2017 issued in related International Application No. PCT/US2016/027764. |
| International Search Report & Written Opinion dated Feb. 11, 2019, issued in related International Application No. PCT/US2018/062766. |
| International Search Report and Written Opinion dated Aug. 2, 2021 issued in corresponding International Application No. PCT/US2021/029836. |
| International Search Report and Written Opinion dated Jan. 31, 2020 issued in related International Application No. PCT/US2019/051447. |
| International Search Report and Written Opinion dated Jul. 30, 2020 issued in related International Application No. PCT/US20/33953. |
| International Search Report and Written Opinion dated Sep. 14, 2020 issued in corresponding International Application No. PCT/US20/30616. |
| International Search Report and Written Opinion dated Sep. 14, 2020 issued in related International Application No. PCT/US20/30616. |
| International Search Report and Written Opinion dated Jul. 14, 2016 issued in related International Application No. PCT/US2016/027764. |
| International Search Report and Written Opinion dated Nov. 7, 2016, issued in related International Application No. PCT/US2016/049415. |
| Japanese Office Action dated Mar. 16, 2021 issued in related Japanese Application No. 2018-510969, with English language summary. |
| Japanese Office Action dated Mar. 31, 2020 issued in related Japanese Application No. 2018-505582, with English translation. |
| Japanese Office Action dated Nov. 17, 2020 issued in related Japanese Application No. 2018-505582, with English translation. |
| Japanese Office Action dated Sep. 15, 2020 issued in related Japanese Application No. 2018-510969, with English language summary. |
| Fermann, M.E. et al. “Ultrawide tunable Er solition fiber laser amplified in Yb-doped fiber”, Optics Letters, vol. 24, No. 20 (Oct. 15, 1999), pp. 1428-1430. |
| Focabex, “Core Structure of Optical Cables” Article (online). Feb. 1, 2002 (retrieved Jan. 8, 2020). Retrieved from the Internet: URL: http://www.focabex.com/library-n/CORE-STRUCTURE-OF-OPTICAL-FIBER-CABLES.pdf. |
| Ghannam, M.T., et al. “Rheological Properties of Poly(dimethylsiloxane)”. Industrial & Engineering Chemistry Research vol. 37, No. 4 (1998) pp. 1335-1340. |
| Golubovic, B. et al. “Optical frequency-domain reflectometry using rapid wavelength tuning of a Cr4+:forsterite laser”, Optics Letters, vol. 22, No. 22 (Nov. 15, 1997), pp. 1704-1706. |
| Harris Jr., U.S. “Tunable Long-Wavelength Vertical-Cavity Lasers: The Engine of Next Generation Optical Networks?”, IEEE Journal On Selected Topics In Quantum Electronics, vol. 6, No. 6 (Nov./Dec. 2000), pp. 1145-1160. |
| Introduction to silicone fluids (https://www.clearcoproducts.com/introduction-to-silicone-fluids.html), retrieved Sep. 24, 2020. |
| Ki, et al. “Diffractive catheter for ultrahigh-resolution spectral-domain volumetric OCT imaging”, Optics Letters, vol. 39, No. 7, Optical Society of America, Mar. 26, 2014, pp. 2016-2019. |
| Kakuta, T. et al. “Behavior of optical fibers under heavy irradiation”, Fusion Engineering And Design, vol. 41 (1998), pp. 201-205. |
| Madigan, Jeremy. “Vascular access: guide catheter selection, usage, and compatibility.” Interventional Neuroradiology, Springer, London (2014), pp. 27-38. |
| Meuwissen, M. et al. “Role of Variability in Microvascular Resistance onFractional Flow Reserve and Coronary Blood Flow Velocity Reserve in Intermediate Coronary Lesions”, Circulation, 103 (2001), pp. 184-187 [online—retrieved on Mar. 7, 2018]. Retrieved from the Internet URL: http://circ.ahajournals.org/content/103/2/184. |
| NKT Photonics. “ESM-12 SingleOmode 12 um core fiber” technical specification sheet. |
| NKT Photonics. “HC-1550-02 Hollow Core Photonic Bandgap Fiber” technical specification sheet. |
| NKT Photonics. “HC-800-02 Hollow Core Photonic Bandgap Fiber” technical specification sheet. |
| Ofili, E.O. et al. “Differential characterization of blood flow, velocity, and vascular resistance between proximal and distal normal epicardial human coronary arteries: Analysis by intracoronary Doppler spectral flow velocity”, American Heart Journal (Jul. 1995), pp. 37-46. |
| Reed, W.A. et al. “Gradient-index fiber-optic microprobes for minimally invasive in vivo low-coherence interferometry”, Optics Letters, vol. 27, No. 20 (Oct. 15, 2002), pp. 1794-1796. |
| Tearney, G.J. et al. “High-speed phase- and group-delay scanning with a grating-based phase control delay line”, Optics Letters, vol. 22, No. 23 (Dec. 1, 1997), pp. 1811-1813. |
| Thorlabs, “Single Wavelength Graded-Index (GRIN) Lenses” Product Catalogue (online). Apr. 9, 2016 (retrieved Jan. 8, 2020). Retrieved from the Internet: URL: https://www.thorlabs.com/NewGroupPage9.cfm?ObjectGroup_ID=1209. |
| Von der Weid, J.P. et al. “On the Characterization of Optical Fiber Network Components with Optical Frequency Domain Reflectometry”, Journal of Lightwave Technology, vol. 15, No. 7 (Jul. 1997), pp. 1131-1141. |
| International Search Report and Written Opinion dated Feb. 9, 2024 issued in International Application No. PCT/US2023/035132. |
| Chinese Office Action dated Oct. 13, 2023 issued in Chinese Application No. 202110324448.9, with English summary. |
| Japanese Office Action dated Nov. 15, 2022 issued in related Japanese Application No. 2021-068226, with English translation. |
| International Preliminary Report on Patentability electronically transmitted to Applicant on Nov. 10, 2022, Issued in related International Application No. PCT/US2021/029836. |
| International Search Report and Written Opinion dated Apr. 14, 2023 issued in related International Application No. PCT/US2023/010508. |
| Atif et al. “Catheters for optical coherence tomography”, Laser Physics Letters, vol. 8, No. 9, (Jul. 1, 2011), pp. 629-646. |
| Extended European Search Report dated Apr. 21, 2023 issued in related European Application No. 20810126.1. |
| Japanese Office Action dated Apr. 25, 2023 issued in related Japanese Application No. 2021-514598, with English summary. |
| Summons To Attend Oral Proceedings dated Mar. 17, 2023 issued in related European Application No. 16842796.1. |
| Brezinski et al. “Optical Coherence Tomography: High-Resolution Imaging in Nontransparent Tissue”, IEEE Journal of Selected Topics in Quantum Electronics, vol. 5, No. 4, Jul./Aug. 1999, pp. 1185-1192. |
| Extended European Search Report dated Mar. 21, 2023 issued in related European Application No. 20798343.8. |
| Jung et al. “Handheld Optical Coherence Tomography Scanner for Primary Care Diagnostics”, IEEE Transactions On Biomedical Engineering, Mar. 2011, vol. 58, No. 3, p. 741-744. |
| Youngquist, R.C. et al.“Optical coherence-domain reflectometry: a new optical evaluation technique”, Optics Letters, vol. 12, No. 3 (Mar. 1987), pp. 158-160. |
| Yun, S.H. et al. “High-speed optical frequency-domain imaging”, Optics Express, vol. 11, No. 22 (Nov. 3, 2003), pp. 2953-2963. |
| Zheng, W. “Optic Lenses Manufactured on Fiber Ends”, IEEE, 978-1-4673-7732-4/15, 2015, pp. 1-10. |
| International Preliminary Report on Patentability dated Dec. 2, 2021 issued in corresponding International Application No. PCT/US2020/033953. |
| Japanese Office Action dated Aug. 2, 2022 issued in corresponding Japanese Application No. 2021-117103, with English translation. |
| International Preliminary Report on Patentability dated Jul. 25, 2024 issued in corresponding International Application No. PCT/US2023/010508. |
| Japanese Office Action dated Sep. 10, 2024 issued in Japanese Application No. 2021564648, with English translation. |
| Extended European Search Report dated Jun. 8, 2022 issued in related European Application No. 21217738.0. |
| European Office Action dated Mar. 14, 2025 issued in European Application No. 20798343.8. |
| International Preliminary Report on Patentability dated Apr. 24, 2025 issued in International Application No. PCT/US2023/035132. |
| Chinese Office Action dated May 16, 2025 issued in Chinese Application No. 202080032004.1, with English summary. |
| Number | Date | Country | |
|---|---|---|---|
| 20220142462 A1 | May 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63017258 | Apr 2020 | US | |
| 62906353 | Sep 2019 | US | |
| 62850945 | May 2019 | US | |
| 62840450 | Apr 2019 | US |
